[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 771
1. Gates EJ, Hirschfield L, Matthews RP, Yap OW: Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc; 2006 Nov;98(11):1814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
  • OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma.
  • METHODS: Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified.
  • CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu.
  • [MeSH-major] Body Mass Index. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / physiopathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Sep;54(3):269-77 [471366.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1140-7 [6936073.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):388-93 [11606102.001]
  • [Cites] JAMA. 1980 Nov 28;244(21):2419-22 [7431569.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):151-8 [16278243.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):939-47 [15870158.001]
  • [Cites] Cancer. 1949 Nov;2(6):964-71, illust [15395195.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):138-43 [10202671.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):25-9 [9577367.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):138-42 [9103403.001]
  • [Cites] Cancer Lett. 1996 Jan 2;98(2):151-5 [8556702.001]
  • [Cites] Am J Obstet Gynecol. 1995 Dec;173(6):1829-34 [8610771.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5693-8 [7585656.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Am J Obstet Gynecol. 1994 Nov;171(5):1193-8 [7977518.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):196-202 [8428691.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2157-62 [7127255.001]
  • [Cites] Pathol Res Pract. 1982 Aug;174(3):237-56 [7145769.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Obstet Gynecol. 1984 Jul;64(1):1-11 [6738931.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):237-8 [3971394.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1452-5 [4027879.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Am J Obstet Gynecol. 1988 Apr;158(4):796-807 [2966586.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):364-6 [2227549.001]
  • [Cites] Rev Fr Gynecol Obstet. 1990 Oct;85(10):513-6 [2263829.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • (PMID = 17128692.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2569783
  •  go-up   go-down


2. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol; 2008 Aug;110(2):196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease.
  • The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.
  • METHODS: Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125.
  • RESULTS: Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed.
  • At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125.
  • CONCLUSION: HE4 is elevated in all stages of endometrial can100cer and is more sensitive in early-stage endometrial cancer compared to CA125.
  • Further investigation of HE4 as a marker for early detection of recurrent endometrial cancer and monitoring response to therapy is warranted.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Epididymal Secretory Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. Female. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Middle Aged. Neoplasm Staging. Sensitivity and Specificity. beta-Defensins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):201-9 [12713981.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1195-7 [12748476.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):292-7 [8088605.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):321-6 [8088608.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1316-9 [8623863.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):967-70 [9038731.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):291-6 [9159340.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):397-400 [10468891.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):315-7 [10475131.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • (PMID = 18495222.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS243878; NLM/ PMC3594093
  •  go-up   go-down


3. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.
  • Endometrium cancer cell lines obtained from three patients were used for this study.
  • CONCLUSION: GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


Advertisement
4. Kurotaki T, Kokoshima H, Kitamori F, Kitamori T, Tsuchitani M: A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit. J Vet Med Sci; 2007 Sep;69(9):981-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit.
  • In a pet rabbit, 2 tumor masses one on each horn were macroscopically seen in the wall of the uterus.
  • The tumor was diagnosed as an adenocarcinoma of the endometrium.
  • While adenocarcinoma cells formed a protrusive mass in the uterine lumen, they also showed an extension into the leiomyoma of the myometrium.
  • By immunohistochemistry, adenocarcinoma stained positive for cytokeratin (MNF116) and leiomyoma stained positive for smooth muscle actin, showing a substantial difference in the cytological nature of these tumor cells.
  • The results may give a further evidence supporting the narrative of the tumor development that an adenocarcinoma of the endometrium extended into leiomyoma of the uterus.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917388.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


6. Bigsby GE 4th, Holloway RW, Weppelman B, Reynolds RB, Williams B: Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up. Gynecol Oncol; 2005 Apr;97(1):256-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up.
  • BACKGROUND: There are few reported cases of cardiac metastasis associated with endometrial cancer (EC) and no reports of long-term survival.
  • A total abdominal hysterectomy with pelvic and para-aortic lymhadenectomy was performed with disease confined to the uterus/cervix.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790471.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Montalto SA, Hakmi A, Moth P, Raju KS, Coutts M, Papadopoulos AJ, Devaja O: Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? Eur J Gynaecol Oncol; 2009;30(1):35-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
  • OBJECTIVE: The purpose of this study was to investigate what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the hysterectomy specimen removed at two UK cancer centres had adverse pathological features or advanced stage disease at the time of presentation.
  • STUDY DESIGN: Ninety-eight patients who were operated on at either the South East London Cancer Centre, London or the Kent Oncology Centre, Maidstone had a histological diagnosis of well differentiated (grade 1) endometrioid adenocarcinoma in their hysterectomy specimen.
  • RESULTS: Of the initial 98 cases, 65 patients (66.3%) were referred with a preoperative curettage showing a well differentiated endometrioid adenocarcinoma, 25 cases (25.5%) were referred with atypical endometrial hyperplasia, seven patients (7.1%) were referred with a moderately differentiated endometrioid adenocarcinoma, and one case (1.0%) was referred with a possible malignant mixed Mullerian tumour.
  • Subsequent histological examination of the hysterectomy specimens revealed that all of these cases had a well differentiated endometrioid adenocarcinoma.
  • From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III.
  • Cases with a preoperative biopsy showing atypical hyperplasia or well differentiated adenocarcinoma should have a preoperative MRI scan or preferably an intraoperative frozen section examination to identify those cases with adverse pathological features which need to be fully staged with pelvic and paraaortic lymphadenectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317254.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


8. Golbar H, Izawa T, Kuwamura M, Ito S, Yamate J: Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig. J Vet Med Sci; 2010 Feb;72(2):253-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig.
  • Grossly, neoplastic enlargement of the uterus was found.
  • Based on these findings, a diagnosis of uterine adenocarcinoma with marked desmoplasia was made.
  • This case is the second report of uterine adenocarcinoma in the miniature pig.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942805.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ: Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol; 2009 Oct;115(1):6-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
  • OBJECTIVE: To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation.
  • METHODS: The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed.
  • Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure.
  • Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632709.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Cutillo G, Cignini P, Visca P, Vizza E, Sbiroli C: Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study. Eur J Surg Oncol; 2007 Sep;33(7):907-10
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study.
  • AIMS: To assess the diagnostic accuracy of endometrial biopsy by means of the hysteroscopic resectoscope (EBHR) in evaluating tumor differentiation in patients with endometrial cancer.
  • METHODS: Between January and December 2005, all the women with a diagnosis of endometrioid adenocarcinoma of the uterus, when admitted to hospital, were enrolled for this study.
  • CONCLUSION: EBHR is a very accurate diagnostic procedure for assessing the preoperative tumor grade in patients with endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrium / pathology. Hysteroscopes. Hysteroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Oct;33(8):1047-8 [17336480.001]
  • (PMID = 17188830.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • The median survival for recurrent endometrial cancer was 5 years.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Arnaoutakis K, Morse AB, Ambika S, Wong G, Parameswaran R: Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). J Clin Oncol; 2009 May 20;27(15_suppl):e17545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Few studies document evaluation of risk of late side effects of cancer therapy.
  • Part 1 evaluation showed that 68 % pts had endometrial adenocarcinoma; 20% cervical cancer; 12% uterine sarcoma or carcinosarcoma.
  • No pts had complete fall risk evaluation, estimated dietary calcium (Ca)/vitamin D intake or documented adequacy of Ca or vit D intake.
  • Counseling for appropriate Ca/vitamin D intake was poor (4%/8%).
  • We have targeted areas for improvement for part 2: vit D level evaluation, assessment of and counseling for adequate of Ca/ vit D intake and WBE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH). J Clin Oncol; 2009 May 20;27(15_suppl):5533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH).
  • : 5533 Background: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging.
  • We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial brush and processed by liquid-based thin-layer cytological preparation protocol.
  • For study, we collected cytology slides from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 50 atypical hyperplasia, and 50 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0/50) of benign, 20% (10/50) of hyperplasia, 76% of atypical hyperplasia (38/50), and 86% (43/50) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 54% in cancer specimens, significantly higher than that in hyperplasia without atypia (13%, p< 0.0001) and atypical hyperplasia (34%, p< 0.0001).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may require close clinical follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer.
  • : e16524 Background: Poor prognostic factors dictating the need for extended surgical staging among endometrial cancer patients can be accurately determined only after laparotomy.
  • This prospective study was conducted to determine the correlation between preoperative serum CA125 and surgicopathologic prognostic factors in endometrial cancer.
  • METHODS: Endometrial cancer patients diagnosed from October 2006 to July 2008 who were eligible for primary surgical treatment were included.
  • RESULTS: Ninety patients with endometrioid endometrial adenocarcinoma were included.
  • It is recommended that serum CA125 determination be part of the preoperative work-up of endometrial cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tretheway D, Gebhardt JG, Dogra VS, Schiffhauer LM: Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature. Int J Gynecol Pathol; 2009 May;28(3):256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature.
  • We report a case of an oncocytic papillary adenocarcinoma of the endometrium in an 89-year-old female with vaginal bleeding.
  • Imaging studies revealed lesions in the uterus, kidneys, pancreas, gluteus, and an enlarged portacaval lymph node.
  • Diagnostic workup included an endometrial biopsy which showed malignant, oncocytic cells in a predominantly papillary pattern.
  • The cells were negative for cytokeratin 903, CAM 5.2, progesterone receptor, CD10, RCC Marker, CA-125, c-kit, and vimentin.
  • Consultation with experts in Gynecologic and Genitourinary pathology returned a diagnosis of "adenocarcinoma compatible with metastatic renal cell carcinoma"--an intriguing possibility worthy of further exploration.
  • To our knowledge, there are no reports in the literature of metastatic oncocytic papillary renal cell carcinoma to the endometrium.
  • The clinical and pathologic features of oncocytic papillary endometrial lesions, including primary and metastatic processes, are reviewed.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620943.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


17. Stilwell G, Peleteiro MC: Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow. Vet Med Int; 2010;2010:727856

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow.
  • The clinical and pathology features of a cow with uterine adenocarcinoma and multiple metastasis are described.
  • Grossly deformed uterus, enlarged iliac lymph nodes, and rosary arranged nodules in the mesentery were felt by rectal palpation.
  • Necropsy and histopathology exam revealed a uterine adenocarcinoma with multiple pulmonary, liver and mesentery metastasis.
  • Uterine adenocarcinoma with metastasis should be included in the differential diagnosis of cows showing weight loss and mild respiratory distress and palpation of numerous firm nodules in the mesentery should be suggestive of neoplasias' metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Vet Med Assoc. 1970 Dec 1;157(11):1577-84 [4098649.001]
  • [Cites] J Am Vet Med Assoc. 1966 Apr 15;148(8):913-5 [5950882.001]
  • [Cites] J Comp Pathol. 1969 Jan;79(1):53-63 [5813284.001]
  • (PMID = 20445789.001).
  • [ISSN] 2042-0048
  • [Journal-full-title] Veterinary medicine international
  • [ISO-abbreviation] Vet Med Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2860195
  •  go-up   go-down


18. Arai T, Watanabe J, Kawaguchi M, Kamata Y, Nishimura Y, Jobo T, Kuramoto H: Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):391-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma.
  • Clear cell adenocarcinoma (CCA) of the endometrium has a poor prognosis, although the biologic features of this rare tumor are not clear.
  • Thirteen cases of CCA were compared with cases of endometrioid adenocarcinoma (EMA) of the endometrium.
  • Immunohistochemical staining for p53; Ki-67; cyclins A, D1, and E; E-cadherin; progesterone receptor (PR)-A and PR-B; P-glycoprotein; MLH1; and MSH2 was performed.
  • No CCAs were positive for PR-A and PR-B.
  • The mechanism of cell-cycle regulation in endometrial CCA is different from that in EMA and may influence its malignant potential.
  • Endometrial CCA is a distinct entity from EMA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Endometrioid / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Cyclin A / analysis. Cyclin D1 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tumor Suppressor Protein p53

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445664.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cyclin A; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


19. Castilho MS, Jacinto AA, Viani GA, Campana A, Carvalho J, Ferrigno R, Novaes PE, Fogaroli RC, Salvajoli JV: Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney. Radiat Oncol; 2006;1:44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney.
  • BACKGROUND: Pelvic Radiotherapy (RT) as a postoperative treatment for endometrial cancer improves local regional control.
  • CASE: We report on a 50 year-old patient with a serous-papiliferous adenocarcinoma of the uterus who was submitted to surgical treatment without lymph node sampling followed by Brachytherapy, and Chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Sep 15;70(5):844-6 [11003368.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9 [14575831.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):376-9 [14751190.001]
  • [Cites] J Urol. 1980 May;123(5):766-7 [7420573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83 [1976615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):174-6 [7901069.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):520-2 [8073523.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):151-5 [7557603.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):57-60 [8841468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):11-7 [16024116.001]
  • (PMID = 17116263.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660561
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


20. Marquette A, Moerman P, Vergote I, Amant F: Second case of uterine mesonephric adenocarcinoma. Int J Gynecol Cancer; 2006 May-Jun;16(3):1450-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second case of uterine mesonephric adenocarcinoma.
  • A second report of an intramural mesonephric adenocarcinoma of the uterus is presented.
  • The histogenesis and clinicopathologic outcome of a surgically staged malignancy add to the insights and experience of this uncommon disorder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mesonephroma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / metabolism. Calbindin 2. Female. Humans. Immunohistochemistry / methods. Neoplasm Invasiveness / diagnosis. S100 Calcium Binding Protein G / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803547.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G
  • [Number-of-references] 18
  •  go-up   go-down


21. Akcaer M, Milman T, Finger PT: Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body. Ophthalmic Surg Lasers Imaging; 2008 May-Jun;39(3):246-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body.
  • A 60-year-old woman with endometrioid adenocarcinoma (stage FIGO II) presented with left eye pain.
  • A Finger iridectomy technique ciliary body tumor biopsy revealed metastatic endometrioid adenocarcinoma.
  • This is the first reported case of endometrioid adenocarcinoma of the uterus metastatic to the uveal tract.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / secondary. Ciliary Body. Endometrial Neoplasms / pathology. Uveal Neoplasms / diagnosis. Uveal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556953.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Vasil'eva EV, Belianin VL: [Serous adenocarcinoma of the uterus: criteria of morphological diagnosis and immunohistochemistry]. Arkh Patol; 2005 Mar-Apr;67(2):25-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serous adenocarcinoma of the uterus: criteria of morphological diagnosis and immunohistochemistry].
  • The analysis of the histopathologic features in 138 patients with uterine serous adenocarcinoma in comparison with 146 patients with uterine endometrioid papillary adenocarcinoma revealed morphological specificities of these carcinomas.
  • Immunohistochemical study found that 66.7% uterine serous adenocarcinomas were negative both to estrogen and progesterone receptors and 86.7% uterine serous adenocarcinomas showed p53 oncoprotein overexpression.
  • The data support the hypothesis that uterine serous adenocarcinoma is a hormone-negative tumor and that mutation of p53 tumor suppressor gene may play a leading role in its carcinogenesis.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Endometrial Neoplasms / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938115.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


24. Shirley S, Devi VS, Krishnamurthy R, Nabhi MV, Majhi U, Selvaluxmy G: Endometrial adenocarcinoma involving both horns of a bicornuate uterus. J Cancer Res Ther; 2010 Jul-Sep;6(3):304-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma involving both horns of a bicornuate uterus.
  • We report a rare case of endometrial adenocarcinoma involving both horns of a bicornuate uterus in a postmenopausal woman.
  • Patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection following an initial positive diagnosis of well differentiated endometrioid adenocarcinoma on endometrial biopsy.
  • Endometrial carcinoma arising in malformed uterus is rare.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Uterus / abnormalities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119258.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


25. Lin CK, Yu MH, Chu TW, Lai HC: Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium. Taiwan J Obstet Gynecol; 2006 Dec;45(4):336-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • OBJECTIVE: Synchronous primary malignant neoplasms of the uterus are uncommon.
  • Patients with synchronous cervical and endometrial cancers are even rarer.
  • We describe a case of cervical squamous cell carcinoma and endometrial endometrioid adenocarcinoma occurring simultaneously in a 47-year-old woman presenting with massive menstrual bleeding.
  • Magnetic resonance imaging revealed a mass over the cervical region and endometrial lesions in the uterine cavity.
  • Surgical exploration disclosed a cervical tumor and erosion of the endometrium.
  • The pathologic findings were compatible with synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • It is practical to pay more attention to the differential diagnosis of primary and metastatic tumors.
  • The second primary cancer that occurs in an individual with endometrial cancer may offer an opportunity for early detection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Female. Humans. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175494.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Takeuchi K, Kitazawa S, Hamanishi S, Inagaki M, Murata K: A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman. Int J Gynecol Cancer; 2006 May-Jun;16(3):1442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman.
  • Although case reports of alpha-fetoprotein (AFP)-producing adenocarcinoma other than hepatocellular carcinoma have gradually increased in number, AFP-producing adenocarcinoma of the endometrium is very rare.
  • Radiologic imaging and endoscopy did not provide evidence of any primary carcinoma in the liver and gastrointestinal tract.
  • To investigate the unknown origin of high AFP, Pap smear of the endometrium followed by fractional curettage was performed and revealed adenocarcinoma of the endometrium.
  • Histologic study showed a mixture of major AFP-negative endometrioid adenocarcinoma and minor medullary proliferation of the AFP-positive hepatoid adenocarcinoma cells with eosinophilic cytoplasm and hyaline globules.
  • The possible existence of AFP-producing adenocarcinoma of the endometrium should be considered in a postmenopausal woman even if there is no vaginal bleeding, when AFP-producing tumor is clinically suspected and the imaging studies fail to confirm the diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / secretion. Carcinoma, Hepatocellular / secondary. Endometrial Neoplasms / secretion. alpha-Fetoproteins / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803544.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 10
  •  go-up   go-down


27. Nishimura Y, Watanabe J, Jobo T, Hattori M, Arai T, Kuramoto H: Cytologic scoring of endometrioid adenocarcinoma of the endometrium. Cancer; 2005 Feb 25;105(1):8-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: Endometrial carcinoma is one of the most frequent malignancies in the female genital tract, and its incidence has been increasing in Japan.
  • The objective of this study was to evaluate the applicability and usefulness of cytologic scoring in assessing the morphologic differentiation of endometrioid adenocarcinomas of the endometrium using endometrial smears.
  • METHODS: Sixty-four endometrial cytologic samples of endometrioid adenocarcinomas of the endometrium were used in this study.
  • All patients underwent endometrial cytology before hysterectomy, and the diagnosis was confirmed by histologic examination of the extirpated uterus.
  • The best cut-off value for distinguishing histologic Grade 1 from the others was a cytologic score of 17, representing a sensitivity of 83% and a specificity of 81%.
  • For distinguishing histologic Grade 3 from the others, the best cut-off value was a cytologic score of 20, representing a sensitivity of 100% and a specificity of 83%.
  • CONCLUSIONS: The cytologic scoring system studied for endometrioid adenocarcinoma was useful for predicting histologic grade and tumor malignant potential.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 American Cancer Society
  • (PMID = 15597380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


28. Kato K, Suzuka K, Osaki T, Itami M, Tanaka N: Primary hepatoid adenocarcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1150-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatoid adenocarcinoma of the uterine cervix.
  • Hepatoid adenocarcinoma is characterized histologically by neoplastic epithelial cells that resemble hepatocellular carcinoma (HCC) and produce alpha-fetoprotein (AFP).
  • We describe a case of hepatoid adenocarcinoma of the uterus that, unlike any other previously reported case, was strictly confined to the cervix.
  • A cervical biopsy demonstrated poorly differentiated adenocarcinoma, and hysterectomy and bilateral salpingo-oophorectomy were subsequently performed.
  • Histologically, the lesion consisted of solid sheets of hepatoid cells accompanied with areas of endometroid adenocarcinoma.
  • The tumor cells showed strong and diffuse cytoplasmic immunoreactivity with AFP in both medullary and adenocarcinoma components.
  • To our knowledge, this is the first report of primary hepatoid adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367323.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 15
  •  go-up   go-down


29. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA: Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol; 2006 Apr;194(4):1119-26; discussion 1126-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
  • OBJECTIVE: The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential.
  • STUDY DESIGN: Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor, progesterone receptor, HER2, AKT, and 4EBP1 proteins in 27 atrophic endometria, 31 grade 1 and 24 grade 3 endometrioid endometrial cancers, and 19 malignant mixed müllerian tumors.
  • RESULTS: Malignant mixed müllerian tumors and grade 3 endometrioid endometrial cancers demonstrated higher levels of AKT and 4EBP1 activation and hormone receptor loss compared with grade 1 endometrioid endometrial cancers and atrophic samples.
  • In endometrial cancer cell-lines, AKT cascade inhibitors decreased cell proliferation by apoptosis and cell cycle arrest.
  • CONCLUSION: AKT cascade activation in grade 3 endometrioid endometrial cancers and malignant mixed müllerian tumors is a novel finding.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Mixed Tumor, Mullerian / drug therapy. Oncogene Protein v-akt / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580307.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA44579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


30. Klopfleisch R, van der Grinten E, Gruber AD: Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama). J Vet Diagn Invest; 2009 Mar;21(2):280-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama).
  • Postmortem examination revealed an infiltrative uterine adenocarcinoma with widespread metastases.
  • The neoplasm completely replaced and infiltrated the myometrium of the uterine body and cervix and metastasized largely to the serosal surfaces of the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma / veterinary. Camelids, New World. Lipomatosis / veterinary. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Uterine Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286516.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


31. Cannon CZ, Godfrey VL, King-Herbert A, Nielsen JN: Metastatic uterine adenocarcinoma in an 8-year-old gilt. J Am Assoc Lab Anim Sci; 2009 Nov;48(6):795-800
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine adenocarcinoma in an 8-year-old gilt.
  • Uterine adenocarcinoma with metastases to the lungs and regional lymph nodes was diagnosed at necropsy.
  • This case represents the first reported uterine adenocarcinoma in a research pig and the first swine uterine neoplasia in which steroid hormone receptor expression was evaluated.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Diagn Invest. 2000 May;12(3):275-8 [10826846.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6965-9 [11687977.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):1037-54 [12826476.001]
  • [Cites] J Vet Diagn Invest. 2003 Nov;15(6):515-22 [14667013.001]
  • [Cites] Toxicol Pathol. 2004 Jul-Aug;32(4):402-7 [15307213.001]
  • [Cites] J Comp Pathol. 1969 Jan;79(1):53-63 [5813284.001]
  • [Cites] J Comp Pathol. 2009 May;140(4):254-9 [19201419.001]
  • [Cites] J Comp Pathol. 1978 Oct;88(4):505-17 [213453.001]
  • [Cites] Vet Q. 1984 Apr;6(2):90-6 [6740896.001]
  • [Cites] J Vet Diagn Invest. 2004 Nov;16(6):587-9 [15586579.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):827-33 [16681769.001]
  • [Cites] Vet Pathol. 2008 Mar;45(2):217-25 [18424838.001]
  • [Cites] Vet Pathol. 1976;13(6):451-2 [1006956.001]
  • (PMID = 19930830.001).
  • [ISSN] 1559-6109
  • [Journal-full-title] Journal of the American Association for Laboratory Animal Science : JAALAS
  • [ISO-abbreviation] J. Am. Assoc. Lab. Anim. Sci.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL069364; United States / NHLBI NIH HHS / HL / HL069364; United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 0 / progesterone receptor B
  • [Other-IDs] NLM/ PMC2786936
  •  go-up   go-down


32. Buchynska LG, Nesina IP: Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma. Exp Oncol; 2006 Jun;28(2):152-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma.
  • AIM: To study correlation links between expression level of proteins p53, p21(WAF1/CIP), p16(INK4) and proliferative potential in human endometrial adenocarcinoma (EC).
  • MATERIAL AND METHODS: The immunohistochemical analysis of expression level of Ki-67, p53, p21(WAF1/CIP) and p16(INK4) was carried out on surgically resected endometrial cancer samples (n = 74).
  • Scrapes of normal endometrium from 10 patients with polyps of cervical canal of the uterus served as the control.
  • RESULTS: The data showed that endometrial malignant tumors possess high proliferative activity (proliferation index was 37.3 +/- 0.2%), overexpression of p53 (labeling index (LI) = 46.1 +/- 0.5%) and high expression of p21(WAF1/CIP) (LI = 11.2 +/- 0.4%) and p16(INK4) (LI = 12.0 +/- 0.2%).
  • In low differentiated endometrial adenocarcinomas the highest level of Ki-67, p53 and p21(WAF1/CIP) expression and lowest content of p16(INK4) protein were observed.
  • CONCLUSION: The indicated markers may be used along with traditional morphological and clinical characteristics for diagnosis of endometrial neoplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Endometrial Neoplasms / diagnosis. Tumor Suppressor Protein p53 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837908.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


33. Jayakrishnan K, Anupama R, Koshy A, Raju R: Endometrial carcinoma in a young subfertile woman with polycystic ovarian syndrome. J Hum Reprod Sci; 2010 Jan;3(1):38-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma in a young subfertile woman with polycystic ovarian syndrome.
  • Adenocarcinoma of the endometrium is a morbid condition in women under 40 years of age with an incidence of 25%.
  • However, patients with anovulatory polycystic ovarian syndrome are at risk of developing endometrial carcinoma.
  • In young women with menstrual abnormalities and polycystic ovarian disease and/or infertility, an endometrial evaluation should be performed.
  • Carcinoma endometrium should be kept in mind while evaluating young women with polycystic ovary syndrome for abnormal uterine bleeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):579-82 [18395778.001]
  • [Cites] Fertil Steril. 2008 Mar;89(3):724.e1-3 [17570366.001]
  • [Cites] Semin Reprod Med. 2008 Jan;26(1):62-71 [18181084.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2798-803 [17602085.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):657-62 [16014120.001]
  • [Cites] BJOG. 2005 Mar;112(3):317-20 [15713146.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):129-32 [11006045.001]
  • [Cites] Fertil Steril. 1996 Jun;65(6):1083-9 [8641477.001]
  • [Cites] Endocrinology. 1995 Jun;136(6):2531-7 [7750475.001]
  • [Cites] Endocr Rev. 1990 Aug;11(3):443-53 [2226350.001]
  • [Cites] Br J Cancer. 1988 Feb;57(2):205-12 [3358913.001]
  • [Cites] Lancet. 2003 May 24;361(9371):1810-2 [12781553.001]
  • [Cites] Lancet. 2002 Jul 20;360(9328):235 [12133671.001]
  • [Cites] Hum Reprod. 1997 Aug;12(8):1649-53 [9308787.001]
  • (PMID = 20607008.001).
  • [ISSN] 1998-4766
  • [Journal-full-title] Journal of human reproductive sciences
  • [ISO-abbreviation] J Hum Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2890909
  • [Keywords] NOTNLM ; Endometrial adenocarcinoma / infertility / polycystic ovaries
  •  go-up   go-down


34. Selim AA, Shaheen S, Lockshin N, Khachemoune A: Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature. Cutis; 2009 Jul;84(1):33-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature.
  • Cutaneous metastases from cancer are relatively uncommon in clinical practice but when present may herald the diagnosis of internal malignancy.
  • The most common sources of primary cancer are the breasts, lungs, large bowel, oral cavity, kidneys, stomach, ovaries, and malignant melanoma.
  • Despite the high incidence of uterine adenocarcinoma, cutaneous metastases are uncommon.
  • The diagnosis of cutaneous metastatic carcinoma hinges on histopathologic evaluation of the involved skin.
  • We discuss and review the diagnosis and management of cutaneous metastasis of uterine adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Skin Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19743722.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Pfister P, Geissbuehler U, Wiener D, Hirsbrunner G, Kaufmann C: Pollakisuria in a dwarf goat due to pathologic enlargement of the uterus. Vet Q; 2007 Sep;29(3):112-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pollakisuria in a dwarf goat due to pathologic enlargement of the uterus.
  • Hydrometra is the most common cause of uterine distension in goats and usually can be resolved by prostaglandin injections.
  • But other pathologies of the uterus can generate a similar syndrome.
  • A laparotomy was performed and an enlarged uterus with 1.5 L of mucous content and cystic ovaries were found and partially removed.
  • A single solid leiomyoma was diagnosed histologically in the uterine wall.
  • Necropsy and pathohistological examination revealed the presence of a metastasized adenocarcinoma of the uterus.
  • In this case, the pollakisuria provoqued by distension of the uterus was not caused by hydrometra, but by neoplasia.
  • The syndrome and the pathogenesis of the adenocarcinoma in consideration of the hormonal status of the patient is discussed.
  • [MeSH-major] Adenocarcinoma / veterinary. Goat Diseases / diagnosis. Leiomyoma / veterinary. Polyuria / veterinary. Uterine Neoplasms / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Female. Goats

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970288.001).
  • [ISSN] 0165-2176
  • [Journal-full-title] The Veterinary quarterly
  • [ISO-abbreviation] Vet Q
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Pena FJ, Gines JA, Duque J, Vieitez V, Martinez-Pérez R, Madejón L, Nuñez Martinez I, Moran JM, Fernández-García S: Endometrial adenocarcinoma and mucometra in a 6-year-old Alaska Malamute dog. Reprod Domest Anim; 2006 Apr;41(2):189-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma and mucometra in a 6-year-old Alaska Malamute dog.
  • Also a very fluid-filled distended uterus and a mass in the distal part of the left uterine horn were found.
  • Histopathological diagnosis was endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / diagnosis. Endometrial Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519728.001).
  • [ISSN] 0936-6768
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Boutet G: [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?]. Gynecol Obstet Fertil; 2006 Nov;34(11):1015-23
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?].
  • [Transliterated title] Dispositif intra-utérin au lévonorgestrel (Mirena) et cancer du sein: que nous apporte la littérature pour la pratique quotidienne?
  • Annual occurrence of breast cancer is constantly increasing in France.
  • In 2000, the number of breast cancer cases for women of 30-49 years was estimated at 9,918, which represents 23.7% of all breast cancer cases diagnosed that year.
  • Because contraception is an important matter for women whose ovarian function survived cancer treatments, the question of whether to use such device on a woman with breast cancer has become a frequent and controversial gynaecological issue.
  • First, whether the use of IUD LNG increases the risk of breast cancer: there is at the moment no "A" level answer available.
  • Second, whether the use of IUD LNG counterbalances the endometrial effects of Tamoxifene: based on a limited level of evidence via a single randomised controlled trial on a small number of patients for one year only, this device appears to be able to prevent benign endometrial modifications.
  • However, there is no conclusive study regarding its effectiveness on the prevention of endometrium adenocarcinoma caused by Tamoxifene.
  • Third, whether a woman with a personal antecedent of breast cancer can safely use DIU LNG: it is necessary to remove it promptly upon suspicion or diagnosis, to dissuade its use in case of current cancer, and, in the event of cancer remission for more than 5 years, to generally avoid this contraceptive method except on a case by case basis and with a regular medical follow-up.
  • [MeSH-minor] Adenocarcinoma / prevention & control. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / prevention & control. Evidence-Based Medicine. Female. France / epidemiology. Humans. Middle Aged. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092752.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptive Agents, Female; 094ZI81Y45 / Tamoxifen; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 59
  •  go-up   go-down


39. Nabli H, Tuller E, Sharpe-Timms KL: Haptoglobin expression in endometrioid adenocarcinoma of the uterus. Reprod Sci; 2010 Jan;17(1):47-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haptoglobin expression in endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Elevated serum haptoglobin (Hp) concentrations have been reported in patients with malignant diseases.
  • We have shown that Hp is produced by and localizes only in the stroma and not the epithelium of endometriotic lesions, which share many characteristics of carcinoma.
  • Furthermore, Hp mRNA and protein are found exclusively in the stroma of eutopic endometrium from women with endometriosis and not those without endometriosis.
  • We hypothesized that characteristic patterns of Hp gene expression and protein localization in endometrioid adenocarcinoma of the uterus may provide insight into the clinical utility of Hp as a tumor marker or alternative therapeutic approach.
  • METHODS: Biopsies of endometrioid adenocarcinoma tumors of the uterus and their adjacent nonaffected endometrium were collected.
  • Normal endometrium was collected from healthy women.
  • RESULTS: Haptoglobin mRNA levels were significantly greater (P < .005) in endometrioid adenocarcinoma and adjacent nonaffected endometrial tissues than normal endometrium.
  • No correlation was found between Hp levels and cancer stage (P = .673) or grade (P = .739).
  • Haptoglobin protein localized in both stromal and glandular epithelial cells of endometrioid adenocarcinoma and their adjacent nonaffected tissue but not in control endometrium.
  • CONCLUSIONS: Our results have identified, for the first time, unique patterns of Hp mRNA expression and protein localization in the stromal and glandular epithelial cells of endometrioid adenocarcinoma of the uterus.
  • We propose that this unique pattern of endometrioid adenocarcinoma Hp expression may be developed as a novel diagnostic marker.
  • Modulation of Hp, with its immunomodulatory and angiogenic properties, may generate novel methods of prevention or treatment for endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Haptoglobins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801537.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins; 0 / RNA, Messenger
  •  go-up   go-down


40. Hsu MI, Chou SY, Lin SE, Liang SJ, Chiu HC, Hsu CS: Very early stage adenocarcinoma arising from adenomyosis in the uterus. Taiwan J Obstet Gynecol; 2006 Dec;45(4):346-9
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very early stage adenocarcinoma arising from adenomyosis in the uterus.
  • OBJECTIVE: Malignant transformations of adenomyosis in premenopausal women with normal endometrium are extremely rare.
  • We report a case of adenocarcinoma arising from an adenomyotic focus in the uterus, which was found unexpectedly in a woman undergoing myomectomy for adenomyosis.
  • She was admitted and underwent myomectomy under the initial diagnosis of uterine leiomyoma.
  • Microscopic studies revealed endometrioid adenocarcinoma, which was a malignant transformation of a focus of adenomyosis in the surgical specimen.
  • The endometrium had normal thickness with mild proliferative activity throughout the cavity.
  • There was no atrophic or hyperplastic change in the whole endometrium.
  • The adenocarcinoma was present exclusively in the myometrium, and a transition between the carcinoma and the adenomyotic glands was observed.
  • CONCLUSION: This case report presents evidence that adenocarcinoma may a rise de novo from an adenomyotic lesion in the uterus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Endometriosis / surgery. Uterine Diseases / surgery
  • [MeSH-minor] Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Middle Aged. Myometrium / pathology. Premenopause

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175497.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Akbulut M, Tosun H, Soysal ME, Oztekin O: Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. Arch Gynecol Obstet; 2008 Jul;278(1):79-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature.
  • OBJECTIVE: An endometrioid adenocarcinoma (EAC) with true trophoblastic differentiation is a rare event with a highly aggressive clinical course.
  • CASE: We report an endometrioid adenocarcinoma of the endometrium in which there was a morphologically conventional-appearing EAC component admixed with multinucleated giant cells and large pleomorphic tumor cells that resembled a choriocarcinoma without an elevated serum level of human chorionic gonadotropin (hCG) in a 42-year-old unmarried woman with a history of abnormal uterine bleeding.
  • Histopathologic study of the specimen showed endometrioid adenocarcinoma extended to the deep myometrium with a focus of hemorrhagic and necrotic tumor composed of multinucleated giant cells, large pleomorphic tumor cells, suggesting choriocarcinomatous differentiation (CD).
  • Immunohistochemical studies demonstrated intense reactivity of tumor cells for human chorionic gonadotropin (hCG) confirming the diagnosis.
  • CONCLUSION: Although endometrioid adenocarcinoma with choriocarcinomatous differentiation is known to behave in a more aggressive course, this disease may have a good prognosis with a clinically indolent course when it is small, and without elevated serum hCG levels.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 24
  •  go-up   go-down


42. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4101-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
  • Matrix metalloproteinase-2 (MMP-2), a member of the zinc-dependent metalloproteinase gene family, plays an important role in cancer invasion and metastasis.
  • The current study aimed to evaluate whether the expression of MMP-2 is associated with survival in patients with endometrial endometrioid adenocarcinoma.
  • The MMP-2 immunoreactive protein was evaluated from endometrioid adenocarcinoma of the endometrium in 112 patients treated at Oulu University Hospital, Finland.
  • These data suggest that MMP-2 immunostaining negativity might be linked with a favourable prognosis in endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Endometrial Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309203.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


43. Rauh-Hain JA, Costaaggini I, Olawaiye AB, Growdon WB, Horowitz NS, del Carmen MG: A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol; 2010;31(3):284-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy.
  • OBJECTIVE: To determine the outcomes in patients with Stage I uterine clear cell carcinoma (UCCC) treated with and without adjuvant therapy, and to compare the outcomes in these patients to that of matched controls, patients with Stage I, grade 3, endometrioid adenocarcinoma of the endometrium (EC).
  • Cases (UCCC) were matched by age, stage, adjuvant therapy, and year of diagnosis to controls consisting of patients with grade 3 EC.
  • These data question the benefit of radiation therapy in UCCC patients with disease confined to the uterus.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Chemotherapy, Adjuvant. Endometrial Neoplasms. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077469.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


44. Fanfani F, Fagotti A, Restaino G, Guerriero M, Scambia G: Endometrial cancer arising in both horns of didelphys uterus in a Down's syndrome woman. Gynecol Oncol; 2006 Jun;101(3):537-9
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer arising in both horns of didelphys uterus in a Down's syndrome woman.
  • BACKGROUND: There are only few reports of endometrial cancer arising in patients with uterine malformations.
  • Down's syndrome is characterized by a reduced risk of solid tumors, and there are no reports about its correlation with uterine malformations.
  • CASE: An endometrial adenocarcinoma arising in both horns of a didelphys uterus of a Down's syndrome woman.
  • CONCLUSION: Uterine malformations and genetical disorders may cause a delayed diagnosis of gynecological cancers.
  • Gynecological examination in asymptomatic patients and differential diagnosis in abnormal uterine bleeding patients should be considered.
  • [MeSH-major] Down Syndrome / complications. Endometrial Neoplasms / complications. Uterus / abnormalities

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487578.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Hayasaka T, Nakahara K, Kojimahara T, Saito-Sekiguchi M, Motoyama T, Kurachi H: Endometrioid adenocarcinoma with a functioning stroma. J Obstet Gynaecol Res; 2007 Jun;33(3):381-3
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with a functioning stroma.
  • A case of a 70-year-old woman with endometrioid adenocarcinoma of the ovary with functioning stroma is presented.
  • The endometrial tissue showed hyperplastic changes.
  • The surgical specimens consisted of a multilocular cystic ovarian tumor of 95 mm in diameter and an enlarged uterus.
  • Histologically, the tumor was composed of proliferating, atypical, columnar cancer cells resembling early secretory endometrial cells, and condensation of plumed stromal cells resembling theca lutein cells.
  • The diagnosis of endometrial adenocarcinoma of the ovary with functioning stroma was made.
  • Mucinous epithelial ovarian tumors most commonly present with estrogenic stroma, although the frequency of endometrioid adenocarcinoma with functioning stroma is very low.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estradiol / blood. Follicle Stimulating Hormone / blood. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578372.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


46. Wong WL, Tay EH: Adenocarcinoma of the abdominal wall. Singapore Med J; 2008 Dec;49(12):e359-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the abdominal wall.
  • We report a rare case of adenocarcinoma confined to the umbilicus.
  • Excision biopsy showed adenocarcinoma with an appearance suggestive of metastasis from an ovarian cystadenocarcinoma.
  • The frozen section of the tumour showed papillary adenocarcinoma.
  • Histology showed adenocarcinoma favouring serous cancer.
  • There was no tumour seen in the ovaries, uterus and omentum.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Wall. Adenocarcinoma, Papillary / diagnosis
  • [MeSH-minor] Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / secondary. Diagnosis, Differential. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Umbilicus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122935.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


47. Pires MA, Seixas F, Palmeira C, Payan-Carreira R: Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma. Reprod Domest Anim; 2010 Jun;45(3):545-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma.
  • Canine endometrial carcinomas are rare, and mostly occur in geriatric bitches.
  • In this work, the uterus of a 10-year-old female Boxer evidencing an endometrial carcinoma on the body of the uterus was used to describe the histopathological features of the tumour and to study its immunophenotype.
  • In this work, a panel of immunomarkers (cytokeratins AE1/AE3 and 14, vimentin, CD10 and Ki-67) was applied to the endometrial carcinoma to establish the staining patterns indicative of the tumour agressiveness and cellular differentiation.
  • This study aims to contribute to the advancement of the knowledge in canine endometrial carcinoma immunophenotype.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / diagnosis. Endometrial Neoplasms / veterinary. Immunohistochemistry / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144037.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


48. Takacs P, De Santis T, Nicholas MC, Verma U, Strassberg R, Duthely L: Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease. J Ultrasound Med; 2005 Nov;24(11):1477-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease.
  • OBJECTIVE: The purpose of this study was to assess postmenopausal women with endometrial fluid collection and the risk of significant endometrial or cervical disease.
  • METHODS: A retrospective chart review was conducted of 343 postmenopausal women with endometrial fluid collection on pelvic sonography.
  • Medical records were reviewed to identify women who underwent an evaluation of the endometrium with endometrial biopsy, hysteroscopy, or hysterectomy after the sonographic examination.
  • Clinical and sonographic characteristics were compared between women with diagnoses of cervical or endometrial cancer or hyperplasia (nonbenign group) and women with benign conditions (benign group).
  • RESULTS: The endometrium was significantly thicker in the nonbenign group compared with the benign group (mean +/- SD, 9.9 +/- 7.4 versus 5.9 +/- 4.1 mm; P = .016).
  • None of the patients with adenocarcinoma of the endometrium had endometrial thickness of 3 mm or less, but 2 with endocervical cancer did.
  • Echogenic fluid in the endometrial cavity was significantly more likely to be found in the nonbenign group compared with the benign group (45.8% versus 4.8%; P < .01).
  • Multivariate logistic regression analysis revealed that echogenic fluid in the endometrial cavity was the only significant risk factor for nonbenign conditions (odds ratio, 10.94; 95% confidence interval, 2.67-44.84; P < .01).
  • CONCLUSIONS: Postmenopausal women with endometrial fluid collection on sonography should undergo endometrial sampling if the endometrial lining is thicker than 3 mm or the endometrial fluid is echogenic.
  • If the lining is 3 mm or less and the endometrial fluid is clear, endometrial sampling is not necessary, but we recommend endocervical sampling to rule out endocervical cancer.
  • [MeSH-major] Endometrium. Postmenopause. Uterine Cervical Diseases / ultrasonography
  • [MeSH-minor] Body Fluids. Female. Humans. Middle Aged. Retrospective Studies. Risk Factors. Uterine Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239648.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Bewtra C, Xie QM, Hunter WJ, Jurgensen W: Ichthyosis uteri: a case report and review of the literature. Arch Pathol Lab Med; 2005 May;129(5):e124-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous metaplasia of endometrium is mostly manifested by morules or nodules of benign nonkeratinizing squamous cells intimately mixed with benign or malignant endometrial glands.
  • It has been described with low-grade adenocarcinoma of the endometrium, as well as with various benign conditions, including hyperplasia, chronic endometritis, and endometrial polyps.
  • To our knowledge, we describe the first case of extensive benign squamous keratinization with underlying endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ichthyosis / diagnosis. Uterus / pathology

  • Genetic Alliance. consumer health - Ichthyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859657.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


50. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Cytology of the pleural effusion showed no malignant cells.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


51. Wicherek L, Popiela TJ, Galazka K, Dutsch-Wicherek M, Opławski M, Basta A, Klimek M: Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes. Gynecol Oncol; 2005 Dec;99(3):622-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes.
  • OBJECTIVE: Endometrium is a specialized organ in which phenomena controlling the level of cell proliferation and apoptosis are marked.
  • The aim of our study was to determine the presence of proteins involved in apoptosis and proliferation: RCAS1, MT and the number of CD56-positive cells and their activity to elucidate their possible role in the development of adenocarcinoma and endometriosis.
  • RESULTS: We found that endometrium during secretory menstrual cycle phase is characterized by significantly higher RCAS1 and higher MT expression than in proliferative phase.
  • Endometrial adenocarcinoma was characterized by significantly increased RCAS1 expression, while MT expression was comparable to the level found in the secretory phase.
  • CONCLUSIONS: The ability of endometrium to determine cytotoxic activity (RCAS1 expression changes) and high protection against DNA damage (MT expression) with concomitant changes in the number of immune cells and their activity, observed in normal endometrium during the menstrual cycle phases seems to be fundamental for pathological features of endometrial adenocarcinoma and endometriosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / biosynthesis. Endometrial Neoplasms / immunology. Endometriosis / immunology. Endometrium / immunology. Menstrual Cycle / immunology. Metallothionein / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CD69 antigen; 0 / EBAG9 protein, human; 0 / Lectins, C-Type; 9038-94-2 / Metallothionein
  •  go-up   go-down


52. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol; 2007 Apr;196(4):402.e1-10; discussion 402.e10-1
Hazardous Substances Data Bank. ROSIGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
  • OBJECTIVE: To examine the effects of metformin and rosiglitazone, alone and in combination, on endometrial histology and ovarian steroid production.
  • RESULTS: Abnormal endometrial histology was found in 3 subjects at baseline, including 1 case of adenocarcinoma of the endometrium in an asymptomatic subject, who was excluded from further study.
  • CONCLUSION: This study provides preliminary evidence that insulin-sensitizing drugs may have beneficial effects on the endometrium, although the exact mechanism beyond improving ovulatory function is still unknown.
  • [MeSH-major] Endometrium / pathology. Metformin / therapeutic use. Ovary / pathology. Polycystic Ovary Syndrome / drug therapy. Thiazolidinediones / therapeutic use

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403436.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NCRR NIH HHS / RR / M01 RR010732
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 9100L32L2N / Metformin
  •  go-up   go-down


53. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Some uterine serous carcinomas are diffusely positive.
  • Similarly, HPV-associated invasive squamous carcinomas are p16-positive, whereas the more common non-HPV-associated neoplasms are largely negative or focally positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


54. Corrado G, Baiocco E, Carosi M, Vizza E: Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril; 2008 Nov;90(5):2006.e5-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.
  • OBJECTIVE: To describe a case of progression of endometrial complex atypical hyperplasia (CAH) to extrauterine endometrioid adenocarcinoma in a patient who had requested fertility-sparing management.
  • SETTING: Division of Gynecologic Oncology, National Cancer Institute "Regina Elena," Rome, Italy.
  • PATIENT(S): A nulliparous 36-year-old woman with endometrial CAH who decided on a conservative approach.
  • INTERVENTION(S): Conservative hysteroscopic resection of the lesion, the surrounding endometrium, and underlying myometrium plus hormone therapy regimen of megestrol acetate (160 mg) daily for 6 months.
  • RESULT(S): Eighteen months after fertility-sparing management, a laparoscopic operation revealed grade 2 endometrium adenocarcinoma with superficial myometrial invasion and a microscopic metastasis of the left ovary and Douglas peritoneum.
  • CONCLUSION(S): Conservative therapy is feasible in carefully selected young women with endometrial CAH.
  • However, close follow-up is required because of possible progression to endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / therapy. Endometrial Neoplasms / pathology. Hysteroscopy. Megestrol Acetate / therapeutic use. Precancerous Conditions / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692828.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


55. Demirol A, Bahce M, Ayhan A, Gurgan T: Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer. Reprod Biomed Online; 2005 Jun;10(6):770-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer.
  • A rare case of a patient with conservatively treated endometrial carcinoma who conceived and delivered a healthy baby after the transfer of embryos with intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD) is presented.
  • A 41-year-old woman had an office hysteroscopy in the infertility work-up and stage I endometrial adenocarcinoma was diagnosed.
  • Repeated office hysteroscopy and endometrial sampling was performed after delivery.
  • The appearance of the endometrium was normal on hysteroscopy, and the histology report was normal.
  • The principal concern with medical therapy is that the lesion cannot be fully evaluated until the hysterectomy is performed, the nodes palpated, and the uterus is sectioned.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Preimplantation Diagnosis. Sperm Injections, Intracytoplasmic

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. MEGESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970008.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EA6LD1M70M / Megestrol
  •  go-up   go-down


56. Mittal K, Da Costa D: Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. Int J Gynecol Pathol; 2008 Jan;27(1):45-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings.
  • 1) to evaluate findings in follow-up hysterectomy specimens after a diagnosis of complex atypical hyperplasia or carcinoma in endometrial polyps (EMPs) for possible significance in management strategies; and 2)to identify features in these polyps, that are predictive of the presence of endometrial hyperplasia or carcinoma in subsequent hysterectomy.
  • Records of all cases of EMPs with endometrial hyperplasia were retrieved from the files of New York University Medical Center from 1993 to 2005.
  • Of the 29 patients with complex atypical hyperplasia within the polyp, 19 out of 29 (66%) patients had hyperplasia of the non-polyp endometrium, and adenocarcinoma was observed in 9 out of 29 (31%) patients on follow-up hysterectomy.
  • The percentage of polyp area involved by the hyperplasia was predictive of finding endometrial disorder in subsequent hysterectomy (P = 0.005).
  • Of the 8 patients with adenocarcinoma in situ (AIS) within the polyp 3 (38%) had myoinvasive adenocarcinoma.
  • In contrast, in cases without AIS, 4 out of 21 (19%) had myoinvasive adenocarcinoma in follow-up hysterectomy.
  • Eight of the nine cases with carcinoma in endometrial polyp had endometrial pathology on hysterectomy.
  • Approximately two thirds of the patients with hyperplasia and 90% of patients with adenocarcinoma in endometrial polyps show endometrial pathology on subsequent hysterectomy.
  • The above findings reinforce the need for hysterectomy especially in postmenopausal women with atypical complex hyperplasia or carcinoma in endometrial polyps even if these changes appear confined to the polyp in initial sampling.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156974.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Vaccaro CA, Bonadeo F, Roverano AV, Peltomaki P, Bala S, Renkonen E, Redal MA, Mocetti E, Mullen E, Ojea-Quintana G, Benati ML, Rivello HG, Clark MB, Lynch JF, Lynch HT: Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register. Dis Colon Rectum; 2007 Oct;50(10):1604-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register.
  • Among the 306 affected members, 197 cases of colorectal cancer were identified (mean age at diagnosis, 52.1 (range, 21-90) years).
  • The most frequent extracolonic tumors were gastric adenocarcinoma in males and endometrium adenocarcinoma in females.
  • A high incidence of breast cancer was observed (16 cases among 155 females, crude rate: 11,594.20/100,000).
  • A novel C deletion at 1910 nucleotide, codon 637, exon 12 of MSH2 gene was identified in a family with a strong aggregation of breast cancer with lack of MSH2 immunohistochemical staining.
  • CONCLUSIONS: Argentine families presented a high incidence of stomach cancer.
  • The elevated incidence of breast cancer and its association with a novel hMSH2 mutation bring to consideration the inclusion of this malignancy as part of the syndrome.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Lynch syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846840.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


58. Kotru M, Chandra H, Singh N, Bhatia A: Localized amyloidosis in endometrioid carcinoma of the uterus: a rare association. Arch Gynecol Obstet; 2007 Oct;276(4):383-4
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized amyloidosis in endometrioid carcinoma of the uterus: a rare association.
  • Amyloidosis of the endometrium is rare and has only been reported as part of a systemic disease.
  • Ultrasonography revealed a growth in the uterine cavity and enlarged internal and external iliac lymph nodes.
  • The histologic diagnosis was that of a well-differentiated endometrioid adenocarcinoma: villoglandular type.
  • CONCLUSION: This is an unusual case of amyloidosis associated with endometrioid carcinoma of the uterus.
  • [MeSH-major] Amyloidosis / complications. Carcinoma, Endometrioid / complications. Endometrial Neoplasms / complications. Uterine Diseases / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17406875.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Yang YP, Zhu YL, Wu WP, Wang ZM, Zhang JM: [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):302-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review].
  • OBJECTIVE: To study the pathologic features, diagnosis, differential diagnosis and biologic behavior of uterine perivascular epithelioid tumor.
  • METHODS: Five cases of uterine perivascular epithelioid cell tumor were studied by light microscopy and immunohistochemistry.
  • CONCLUSIONS: Perivascular epithelioid cell tumor is a rare mesenchymal tumor of uterus, with distinctive histologic and immunohistochemical features.
  • It should be distinguished from clear cell carcinoma and epithelioid leiomyoma of uterus.
  • Positivity for melanocytic markers (especially HMB45) plays an important role in the diagnosis of this tumor.
  • In general, the tumor is categorized as benign, with uncertain malignant potential and malignant.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Neoplasm Proteins / metabolism. Perivascular Epithelioid Cell Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Leiomyoma, Epithelioid / pathology. Melanoma-Specific Antigens. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706136.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 24
  •  go-up   go-down


60. Preissel AK, Brugger N, Stassen T, Nuss K: [Treatment of a uterine adenocarcinoma in a miniature pig by ovariohysterectomy]. Schweiz Arch Tierheilkd; 2009 May;151(5):229-32
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of a uterine adenocarcinoma in a miniature pig by ovariohysterectomy].
  • A ventral midline approach was chosen to remove the ovaries and uterus, which contained brown fluid and multifocal masses in the uterine wall.
  • Histological examination of the uterine masses revealed leiomyoma, cystic hyperplasia and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Hysterectomy / veterinary. Ovariectomy / veterinary. Swine Diseases / surgery. Swine, Miniature. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421955.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


61. Faruqi SA, Harsch C, Saquib M, Noumoff J: Clonal Variation within an Adenocarcinoma of the Endometrium Cultured in Different Substrates and Media. J Assoc Genet Technol; 2009;35(1):5-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal Variation within an Adenocarcinoma of the Endometrium Cultured in Different Substrates and Media.
  • An adenocarcinoma of the endometrium was cultured separately in four different combinations of two substrates (normal tissue culture plastic and PrimariaTM) and two media (RPMI-1640 and serum free LHC-9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252255.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Hirabayashi K, Yasuda M, Kajiwara H, Nakamura N, Sato S, Nishijima Y, Mikami M, Osamura RY: Clear cell adenocarcinoma arising from adenomyosis. Int J Gynecol Pathol; 2009 May;28(3):262-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising from adenomyosis.
  • An elevated level of CA125 in the blood favored a diagnosis of malignant uterine body tumor, but was not confirmed by endometrial cytology and biopsy.
  • Resection of the uterus revealed a solid whitish tumor in the myometrium that was diagnosed as clear cell adenocarcinoma (CCA) arising from adenomyosis.
  • There were transitions between endometrial epithelium of adenomyosis, noninvasive CCA, and invasive CCA.
  • Immunohistochemical expression of hepatocyte nuclear factor-1beta supported the diagnosis of CCA.
  • Malignant tumor arising from adenomyosis should be considered as a differential diagnosis when the serum level of tumor markers such as CA125 is high and when the tumor is intramyometrial.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. CA-125 Antigen / blood. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620944.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


63. Kawate S, Takeyoshi I, Ikota H, Numaga Y, Sunose Y, Morishita Y: Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon. Jpn J Clin Oncol; 2005 Mar;35(3):154-7
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon.
  • This report presents a case of endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon following total abdominal hysterectomy and bilateral salpingo-oophorectomy for leiomyoma of the uterus and infiltrating pelvic endometriosis, and hormone replacement therapy.
  • Based on the diagnosis of mesocolonic tumor, sigmoidectomy with lymph node resection was performed.
  • The tumor cells were immunopositive for cytokeratin 7, but negative for cytokeratin 20, and the tumor was histologically diagnosed as endometrioid adenocarcinoma of the mesocolon.
  • Hyperestrogenism has been implicated as a risk factor for the development of cancer from endometriosis.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Endometriosis / pathology. Sigmoid Diseases / pathology. Sigmoid Neoplasms / etiology
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Colon, Sigmoid / blood supply. Estrogen Replacement Therapy / adverse effects. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Leiomyoma / surgery. Lymph Node Excision. Mesentery / pathology. Middle Aged. Ovariectomy. Postoperative Period. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741306.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Han CP, Kok LF, Wang PH, Wu TS, Tyan YS, Cheng YW, Lee MY, Yang SF: Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol; 2009 Jun;22(6):797-806
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
  • Endocervical adenocarcinomas and endometrial adenocarcinomas are malignancies that affect uterus; however, their biological behaviors are quite different.
  • The purpose of this study is to evaluate four different scoring methods of p16(INK4a) immunohistochemical staining in distinguishing between primary endocervical adenocarcinomas and endometrial adenocarcinomas from limited sizes of tissue specimens.
  • A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissue from hysterectomy specimens, including 14 endocervical adenocarcinomas and 21 endometrial adenocarcinomas.
  • Of the four scoring methods for p16(INK4a) expression, Method Nucleus, Method Dominant Cytoplasm or Nucleus, and Method Mean of Cytoplasm plus Nucleus showed significant (P values <0.05), but Method Cytoplasm did not show significant (P=0.432), frequency distinction between endocervical adenocarcinomas and endometrial adenocarcinomas.
  • According to the data in this tissue microarray study, Method Nucleus is the most convenient and efficient method to distinguish between endocervical adenocarcinomas and endometrial adenocarcinomas.
  • Method Cytoplasm is of no use in the diagnostic distinction between endocervical adenocarcinomas and endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Endometrial Neoplasms / diagnosis. Tissue Array Analysis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347018.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


65. Romero FR, Fucs M, Castro MG, Garcia CR, Fernandes Rde C, Perez MD: Adenocarcinoma of persistent müllerian duct remnants: case report and differential diagnosis. Urology; 2005 Jul;66(1):194-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of persistent müllerian duct remnants: case report and differential diagnosis.
  • Persistent müllerian duct syndrome is an unusual disorder characterized by cryptorchidism and retention of müllerian derivatives (uterus, fallopian tubes, and upper vagina).
  • We report the case of a 39-year-old man with this syndrome in association with adenocarcinoma from the retained müllerian remnants of probable endocervical origin.
  • To our knowledge, this is the first report of an endocervical adenocarcinoma associated with persistent müllerian duct syndrome.
  • [MeSH-major] Adenocarcinoma / complications. Cryptorchidism / complications. Mullerian Ducts / abnormalities
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009404.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Kraft O: Incidental diagnosis of uterine cancer on 99mTc-dimercaptosuccinic acid renal scintigraphy. Hell J Nucl Med; 2005 May-Aug;8(2):132-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental diagnosis of uterine cancer on 99mTc-dimercaptosuccinic acid renal scintigraphy.
  • A computerized tomography showed a very large uterus, sized 19 x 10 cm, with myomatous nodes, calcifications and disintegration cavities.
  • Histopathology showed a myomatous uterus with an adenocarcinoma which also affected both ovaria.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Kidney / radionuclide imaging. Pyelonephritis / radionuclide imaging. Radioisotope Renography / methods. Technetium Tc 99m Dimercaptosuccinic Acid. Uterine Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hell J Nucl Med. 2005 Sep-Dec;8(3):176 [16390027.001]
  • (PMID = 16142257.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid
  •  go-up   go-down


67. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer; 2006 Feb 15;106(4):812-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
  • BACKGROUND: Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States, accounting for approximately 36,000 diagnoses of invasive carcinoma annually.
  • The most common histologic type, endometrioid adenocarcinoma (EC), accounts for 75-80% of patients.
  • The objective of this work was to estimate the prevalence of concurrent carcinoma in women with a biopsy diagnosis of the precursor lesion, atypical endometrial hyperplasia (AEH).
  • METHODS: This prospective cohort study included women who had a community diagnosis of AEH.
  • Of these, 17 women were not included in the analysis: Two patients had unreadable slides because of poor processing or insufficient tissue, 2 patients had only slides that were not endometrial, the slides for 5 patients were not available for review, and 8 of the hysterectomy specimens were excluded because they showed evidence of interval intervention, either progestin effect or ablation.
  • The study panel review of the AEH biopsy specimens was interpreted as follows: 74 of 289 specimens (25.6%) were diagnosed as less than AEH, 115 of 289 specimens (39.8%) were diagnosed as AEH, and 84 of 289 specimens (29.1%) were diagnosed as endometrial carcinoma.
  • In 5.5% (16 of 289 specimens), there was no consensus on the biopsy diagnosis.
  • The rate of concurrent endometrial carcinoma for analyzed specimens was 42.6% (123 of 289 specimens).
  • Among the women who had hysterectomy specimens with carcinoma, 14 of 74 women (18.9%) had a study panel biopsy consensus diagnosis of less than AEH, 45 of 115 women (39.1%) had a study panel biopsy consensus diagnosis of AEH, and 54 of 84 women (64.3%) had a study panel diagnosis of carcinoma.
  • Among women who had no consensus in their biopsy diagnosis, 10 of 16 women (62.5%) had carcinoma in their hysterectomy specimens.
  • CONCLUSIONS: The prevalence of endometrial carcinoma in patients who had a community hospital biopsy diagnosis of AEH was high (42.6%).
  • When considering management strategies for women who have a biopsy diagnosis of AEH, clinicians and patients should take into account the considerable rate of concurrent carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Hyperplasia / complications. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • (PMID = 16400639.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


68. Mylonas I, Makovitzky J, Shabani N, Richter DU, Kuhn C, Jeschke U, Briese V, Friese K: Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue. Eur J Obstet Gynecol Reprod Biol; 2005 Jan 10;118(1):101-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue.
  • Therefore, the aim of this study was to determine the frequency and tissue distribution of LIF in normal, hyperplastic and malignant endometrium.
  • STUDY DESIGN: Paraffin-fixed endometrial tissue was obtained from normal premenopausal women (n = 15), endometrial hyperplasia (n = 20), endometroid adenocarcinoma (n = 32) and endometrial polyps (n = 9).
  • RESULTS: The lowest expression of LIF was observed in endometrial adenocarcinomas compared to all groups, while endometrial polyps expressed the highest LIF immunostaining.
  • The highest expression of LIF was observed in endometrial polyps.
  • Simple hyperplasia showed a significantly higher LIF expression than proliferative endometrium and adenocarcinoma.
  • Adenomatous hyperplasia (AH) grade I-III had a significantly higher LIF expression than adenocarcinoma.
  • The lowest expression of LIF was observed in adenocarcinoma, being statistically significant compared to all groups.
  • CONCLUSION: LIF was immunohistochemically demonstrated in normal, hyperplastic and malignant endometrial tissue, suggesting a widespread but complex role for LIF in hyperplastic and malignant endometrial growth regulation.
  • AH I-III also expressed LIF with statistically higher immunostaining than adenocarcinoma.
  • Since AH III can be considered as a precursor of endometrial cancer, LIF could be a marker of cell transformation.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Immunohistochemistry. Interleukin-6 / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Female. Humans. Leukemia Inhibitory Factor. Polyps / chemistry. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596282.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor
  •  go-up   go-down


69. Xiaoxin M, Yingnan J, Yanxia L, Shu L, Yuanqi H, Hongwei L: Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. Int J Gynecol Cancer; 2009 Oct;19(7):1182-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth.
  • OBJECTIVE: : To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments.
  • METHODS: : The effects on Ishikawa adenocarcinoma endometrium cell proliferation and cell cycle of aspirin at different intervals and concentrations were determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method and flow cytometry; cell morphous change after the effect of aspirin was observed with transmission electron microscope; and the effect of aspirin on B-cell lymphoma/leukemia-x, long (Bcl-xl) proteinum expression was determined with Western blot.
  • RESULTS: : Aspirin had a significant depressant effect on human Ishikawa adenocarcinoma endometrium cell proliferation, and the effect showed time and dose dependence (P < 0.05).
  • CONCLUSIONS: : Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression.
  • [MeSH-major] Adenocarcinoma / pathology. Aspirin / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Endometrial Neoplasms / pathology

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820387.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; R16CO5Y76E / Aspirin
  •  go-up   go-down


70. Gonçalves R, Linhares E, Albagli R, Valadão M, Vilhena B, Romano S, Ferreira CG: Occurrence of other tumors in patients with GIST. Surg Oncol; 2010 Dec;19(4):e140-3
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Evaluate the presence of other tumors in cohort of patients with GIST treated at a cancer treatment referral center - INCA.
  • Immunohistological diagnosis was confirmed by a pathologist specialized in sarcomas.
  • The mean size of lesions was 4.79 cm (0.3-15 cm), with malignant potential low/very low in 7 cases (50%), intermediate in 5 cases (35.7%) and high in 2 cases (14.3%).
  • The diagnosis of GIST was incidental in 6 cases and in one case the non-GIST tumor was incidental.
  • The non-GIST tumors were most frequent in the stomach (adenocarcinoma), in 4 cases (28.5%) and colon/rectum (adenocarcinoma) in 4 other cases.
  • The other sites involved were breast (ductal carcinoma), kidney (clear cell carcinoma), prostate (adenocarcinoma), endometrium (adenocarcinoma), ovary (adenocarcinoma) and adrenal (neuroblastoma), with one case each.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Brazil / epidemiology. Child. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Rectal Neoplasms / epidemiology. Retrospective Studies. Stomach Neoplasms / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20675121.001).
  • [ISSN] 1879-3320
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Wallace AE, Gibson DA, Saunders PT, Jabbour HN: Inflammatory events in endometrial adenocarcinoma. J Endocrinol; 2010 Aug;206(2):141-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory events in endometrial adenocarcinoma.
  • Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries.
  • Many of the established risk factors for developing endometrial cancer are associated with excess exposure to oestrogen unopposed by progesterone.
  • However, a number of risk factors also promote inflammation, another feature proposed to influence cancer development.
  • The human cycling endometrium undergoes regular and cyclical episodes of inflammation.
  • Moreover, hormonal and genetic changes that occur early in the development of endometrial adenocarcinoma can exacerbate the local inflammatory environment.
  • Via alterations in the expression of local mediators and immune cell function, these may contribute to the development of endometrial cancer.
  • This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma.
  • Manipulation of inflammatory pathways may therefore represent a therapeutic target in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Inflammation

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406782.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127685844; United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01; United Kingdom / Medical Research Council / / U.1276.00.002.00005.01 (85844); United Kingdom / Medical Research Council / / U1276.00.002.00005.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Chemokines; 0 / Cytokines; 0 / Estrogens; 0 / Glucocorticoids; 0 / KRAS protein, human; 0 / NF-kappa B; 0 / Prostaglandins; 0 / Proto-Oncogene Proteins; 4G7DS2Q64Y / Progesterone; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 190
  •  go-up   go-down


72. Wani Y, Notohara K, Tsukayama C: Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):346-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature.
  • Mesonephric adenocarcinoma (MA) is a rare tumor of the female genital tract, mainly in the cervix and vagina, which is usually associated with mesonephric remnants or mesonephric hyperplasia.
  • In the uterus corpus, MA is as rare as mesonephric structures, and only a few cases have been previously reported.
  • Here, we report a rare case of MA of the uterine corpus.
  • Abdominal computed tomography scan confirmed a uterine tumor measuring 8.6 cm.
  • In addition, the ductal pattern simulating endometrioid adenocarcinoma was also noted.
  • Other elements consisted of a retiform pattern, serous adenocarcinoma-like papillary budding, and glomeruloid morphology.
  • We review the previously published cases of MA and discuss the principal differential diagnosis of MA in the uterine corpus.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580312.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


73. Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y: Carcinosarcoma of the uterus: radiologic-pathologic correlations with magnetic resonance imaging including diffusion-weighted imaging. Magn Reson Imaging; 2008 Dec;26(10):1446-50
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the uterus: radiologic-pathologic correlations with magnetic resonance imaging including diffusion-weighted imaging.
  • The authors describe the MRI findings, including diffusion-weighted imaging findings, of histopathologically proven uterine carcinosarcoma in four postmenopausal women.
  • In the remaining patient, diffusion-weighted and ADC mapping images clearly distinguished components of adenocarcinoma from sarcoma.
  • Diffusion-weighted images were found to demonstrate complicated tissue components in carcinosarcomas of the uterus, and thus, which may be useful for the diagnosis of this disease.
  • [MeSH-major] Carcinosarcoma / pathology. Magnetic Resonance Imaging / methods. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501546.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


74. Hentati D, Belghith B, Kochbati L, Driss M, Maalej M: Clear cell carcinoma of the uterus. Tunis Med; 2010 Apr;88(4):230-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the uterus.
  • AIM: The aim of this study was to determine the characteristics and outcome of patients presenting with clear cell carcinoma (CCC) of the endometrium treated in a single institution.
  • METHODS: We reviewed the records of patients treated in the Salah-Azaiz institute for CCC of the endometrium.
  • The mean age at diagnosis was 64 years (50 to 84 yers).
  • CONCLUSION: Extrauterine extension is frequent at diagnosis and not correlated to classical risk factors observed in endometrioid carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446254.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


75. Morgan J, Sadler MA: Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. Emerg Radiol; 2010 Jan;17(1):65-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report.
  • Endometrial carcinoma is the most common gynecologic cancer in the United States.
  • Uterine papillary serous carcinoma comprises approximately 5-10% of endometrial carcinomas.
  • This aggressive carcinoma typically occurs in older women, characteristically arising on atrophic endometrium.
  • We present a case of acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with diffuse peritoneal psammomatous implants.
  • [MeSH-major] Cystadenocarcinoma, Papillary / complications. Cystadenocarcinoma, Serous / complications. Endometrial Neoplasms / complications. Gastric Outlet Obstruction / etiology
  • [MeSH-minor] Abdomen, Acute / diagnostic imaging. Aged. Contrast Media. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 1990;9(2):110-21 [2332269.001]
  • [Cites] Am J Clin Pathol. 1972 Mar;57(3):297-302 [4259707.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jun;182(6):1534-6 [15150003.001]
  • [Cites] Am J Pathol. 1961 Oct;39:499-510 [13752576.001]
  • [Cites] Lab Invest. 1980 Sep;43(3):287-96 [7401638.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):849-62 [9669347.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(1):46-50 [8472732.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Am J Obstet Gynecol. 1971 Jan 1;109(1):113-8 [4321483.001]
  • [Cites] Radiology. 1986 Mar;158(3):649-52 [3945732.001]
  • [Cites] Cancer. 1972 May;29(5):1326-35 [5021621.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • (PMID = 19132421.001).
  • [ISSN] 1438-1435
  • [Journal-full-title] Emergency radiology
  • [ISO-abbreviation] Emerg Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


76. Shaco-Levy R, Piura B: Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma. J Obstet Gynaecol Res; 2008 Apr;34(2):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma.
  • Müllerian carcinosarcoma is currently regarded as a metaplastic (sarcomatous) carcinoma.
  • Only five cases of pure ovarian adenocarcinoma recurring as carcinosarcoma have been documented in the literature.
  • There are no documented cases of endometrial adenocarcinoma recurring as metaplastic carcinoma.
  • We report of a case of endometrial adenocarcinoma, endometrioid type, recurring as metaplastic carcinoma showing sarcomatous differentiation.
  • The tumor evolution in this case supports the prevailing opinion that Müllerian carcinosarcomas are derived from carcinomas and represent tumor progression.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinosarcoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412798.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Ibáñez Pinto A, Fernández Salgado E, Castro Ortiz E, Baltar Arias R, Vázquez Vázquez S, Ledo Barro L, Vázquez San Luis J, Vázquez Astray E: [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy]. Gastroenterol Hepatol; 2007 Nov;30(9):530-4
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
  • [Transliterated title] Hemorragia digestiva de origen incierto por un adenocarcinoma endometrial metastásico. Respuesta al tratamiento hormonal.
  • BACKGROUND: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • A computed tomography scan showed extensive lymphatic, abdominal and pelvic recurrence of the cancer.
  • Control of bleeding and a 22-month survival were obtained after treatment with oral medroxyprogesterone acetate.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Gastrointestinal Hemorrhage / etiology. Medroxyprogesterone Acetate / therapeutic use. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / secondary. Retroperitoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980130.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Number-of-references] 19
  •  go-up   go-down


78. Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, Nakagawa S, Yano T, Taketani Y, Fukayama M: Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol; 2010 May;29(3):273-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear.
  • Primary adenocarcinoma of the fallopian tube is an uncommon female genital tract tumor.
  • In situ or minimally invasive tubal cancer often poses a diagnostic challenge because of the absence of specific clinical and radiological findings.
  • Here, we report a rare case of bilateral microscopic fallopian tube cancer that initially presented with malignant findings in an endometrial cytologic smear.
  • An endometrial smear performed during a routine checkup revealed clusters of malignant cells.
  • During the clinical diagnosis of endometrial cancer, she underwent bilateral salpingo-oophorectomy, total hysterectomy, and partial omentectomy.
  • Histologically, no carcinoma was found in the uterus or ovaries.
  • In toto sectioning of the fallopian tubes and their fimbriated ends revealed minute foci of serous adenocarcinoma in the left tubal mucosa and right fimbria.
  • In situ adenocarcinoma components were present in both lesions.
  • Microinvasive carcinoma was observed in the right fimbria.
  • Although there was no macroscopic dissemination in the peritoneum at the time of surgery, positive intraoperative peritoneal cytology suggests that the patient was at risk of developing peritoneal serous carcinoma if not treated.
  • Clinicians and pathologists should consider the possibility of early tubal cancer when there is no clinically detectable pelvic mass, and malignant cells appear in endometrial cytology specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407329.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG: Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol; 2009 Jun;113(3):316-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
  • OBJECTIVES: Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor.
  • C) >3 mm and < or =5 mm and D) >5 mm.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hysterectomy. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345400.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Sánchez Anguiano LF, Puente Ledesma L, Lares Bayona EF, Milla Villeda RH: [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis]. Ginecol Obstet Mex; 2007 Sep;75(9):501-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis].
  • [Transliterated title] Receptores de estrógenos en la hiperplasia y el adenocarcinoma de endometrio: estudio inmunohistoquímico con análisis de imagen.
  • BACKGROUND: The endometrium is a very dynamic organ that experience several half-full processes by the ovarian secretion of estradiol and progesterone.
  • The effect of hormones steroids, in the epithelial cells, endoteliales and estromales of the endometrium, is influenced by receptors of estrogens and progesterone.
  • OBJECTIVE: determine if there are any differences in the density of the estrogen receptors (ER) between the normal endometrial, the simple and complex hyperplasia, the atypical hyperplasia and the.
  • We included 143 samples that were knit together in 5 categories of the following way: Normal endometrial (n = 38), Simple hyperplasia (n = 58), Complex hyperplasia (n = 22), Atypical hyperplasia (n = 9), Adenocarcinoma (n = 16).
  • RESULTS: there were no statistical significant differences on the cell density with ER between the normal endometrial and the simple and complex hyperplasia.
  • The estrogen receptors are decreased in the atypical hyperplasia and the endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Endometrial Neoplasms / chemistry. Receptors, Estrogen / analysis
  • [MeSH-minor] Endometrial Hyperplasia. Female. Humans. Immunohistochemistry. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293624.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


81. Healy KA, Carney KJ, Osunkoya AO: Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature. ScientificWorldJournal; 2010;10:1714-22
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature.
  • Endometriosis is characterized by endometrial-like tissue outside the uterus, primarily on the pelvic peritoneum, ovaries, and rectovaginal septum, and, in rare cases, within the urinary tract (1-3%).
  • Although endometriosis is a benign condition, malignant transformation of endometriosis is a well-described phenomenon.
  • A case of endometrioid adenocarcinoma in the native ureter of a postmenopausal renal transplant patient presented with painless gross hematuria and hydroureteronephrosis.
  • Endoscopic biopsies of the native left ureteral mass showed endometrioid adenocarcinoma, grade II-III.
  • Final pathology confirmed endometrioid adenocarcinoma, grade II-III, arising in a background of endometriosis with negative perirectal lymph nodes.
  • This case of ureteral endometrioid adenocarcinoma highlights the importance of obtaining a careful history and maintaining a high index of suspicion for malignant degeneration, especially in the context of hyperestrogenism.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Kidney Transplantation. Ureter / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842317.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


82. Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N, Thomas G, Covens A, Khalifa MA: Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol; 2008 Jun;129(6):912-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma.
  • To evaluate the value of lymphovascular invasion (LVI) in endometrial endometrioid adenocarcinoma (EEA) as a predictor for distant recurrence, we analyzed the histopathologic features of 513 consecutive cases of nonsurgically staged EEA limited to the uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480008.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Puppa G, Shozu M, Perin T, Nomura K, Gloghini A, Campagnutta E, Canzonieri V: Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report. BMC Cancer; 2007;7:103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
  • BACKGROUND: Malignant transformation of adenomyosis is a very rare event.
  • CASE PRESENTATION: The patient was a 57-year-old woman with a slightly enlarged uterus, who underwent total hysterectomy and unilateral adnexectomy.
  • On gross inspection, the uterine wall displayed a single nodule measuring 5 cm and several small gelatinous lesions.
  • A few of these glands were transformed into a moderately differentiated adenocarcinoma.
  • The endometrium was completely examined and tumor free.
  • The carcinoma was, therefore, considered to be an endometrioid adenocarcinoma arising from adenomyosis.
  • Four months later, an ultrasound scan revealed enlarged pelvic lymph nodes: a cytological diagnosis of metastatic adenocarcinoma was made.
  • Immunohistochemical studies showed an enhanced positivity of the tumor site together with the neighbouring adenomyotic foci for estrogen receptors, aromatase, p53 and COX-2 expression when compared to the distant adenomyotic glands and the endometrium.
  • CONCLUSION: Adenocarcinoma in adenomyosis may be affected by local hormonal influence and, despite its small size, may metastasize.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenomyoma / pathology. Endometrial Neoplasms / pathology. Leiomyoma / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Obstet Invest. 1999;48 Suppl 1:21-8 [10559661.001]
  • [Cites] Am J Obstet Gynecol. 1961 Aug;82:408-16 [13766580.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):18-22 [11006024.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):308-13 [11350616.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):239-45 [12068169.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] Am J Reprod Immunol. 2002 Jul;48(1):50-6 [12322896.001]
  • [Cites] Hum Reprod. 2002 Oct;17(10):2725-36 [12351554.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):406-8 [15005792.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 2004 Apr;33(2):140-4 [15052180.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):94-8 [15068832.001]
  • [Cites] Semin Reprod Med. 2004 Feb;22(1):51-60 [15083381.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):1004-6 [15361215.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):483-8 [15863148.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 May;95(1-5):57-62 [16024248.001]
  • [Cites] Hum Reprod Update. 2006 Jan-Feb;12(1):49-56 [16123052.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Jan 1;124(1):101-5 [16456945.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2376-85 [16710036.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1673-8 [16884383.001]
  • [Cites] Maturitas. 2007 Feb 20;56(2):190-7 [16963204.001]
  • [Cites] Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):827-32 [7446615.001]
  • [Cites] Obstet Gynecol. 1986 Jan;67(1):145-8 [3940328.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(4):265-71 [8236823.001]
  • [Cites] Eur J Gynaecol Oncol. 1994;15(6):418-23 [7875156.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):241-6 [8751556.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12):4474-80 [9851796.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):141-4 [10461008.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):379-88 [10786803.001]
  • (PMID = 17584489.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; EC 1.14.14.1 / Aromatase; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC1913924
  •  go-up   go-down


84. Zeeshan-ud-din, Ahsan A: Vaginal clear cell adenocarcinoma with associated Müllerian duct anomalies, renal agenesis and situs inversus: report of a case with no known in-utero exposure with diethyl stilboestrol. J Pak Med Assoc; 2009 Aug;59(8):568-70
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal clear cell adenocarcinoma with associated Müllerian duct anomalies, renal agenesis and situs inversus: report of a case with no known in-utero exposure with diethyl stilboestrol.
  • On evaluation, she was diagnosed as a case of vaginal clear cell adenocarcinoma (VCCA) along with associated Müllerian duct anomalies including didelphys uterus with double vagina; left sided renal agenesis and situs inversus.
  • Although VCCA is strongly linked to in-utero exposure with Diethyl stillboestrol (DES), this patient had no known history regarding such exposure.
  • Also, only a few cases have been described in the literature in which this tumour was seen in association with Müllerian duct anomalies and renal agenesis; in the absence of known DES exposure.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Kidney / abnormalities. Mullerian Ducts / pathology. Situs Inversus / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Carcinogens / toxicity. Diethylstilbestrol / toxicity. Female. Humans. Pregnancy. Prenatal Exposure Delayed Effects. Uterus / abnormalities. Vagina / abnormalities


85. Toyoda M, Satoh T, Takano K, Sato NO, Oki A, Tsunoda H, Yoshikawa H: Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium. Int J Clin Oncol; 2005 Dec;10(6):444-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium.
  • Patients with ovarian cancer with clear cell histology often have venous thromboembolism (VTE) even before surgery.
  • In view of the possible association between clear cell histology and VTE in endometrial cancer, we measured the plasma levels of thrombin-antithrombin III complex (TAT) and D-dimer (DD) in the preoperative examinations of a patient with clear cell adenocarcinoma of the endometrium.
  • Ultrasound Doppler examination and lung perfusion scintigraphy just before surgery revealed a thrombosis in the left popliteal vein and a pulmonary embolism.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Endometrial Neoplasms / complications. Thromboembolism / complications. Thromboembolism / diagnosis
  • [MeSH-minor] Aged. Antithrombin III. Female. Fibrin Fibrinogen Degradation Products / metabolism. Humans. Hysterectomy. Ovariectomy. Peptide Hydrolases / blood. Popliteal Vein. Preoperative Care. Pulmonary Embolism / blood. Pulmonary Embolism / complications. Pulmonary Embolism / diagnosis. Venous Thrombosis / blood. Venous Thrombosis / complications. Venous Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2001 Jul;20(3):252-9 [11444201.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Thromb Res. 1998 Jul 15;91(2):101-4 [9722026.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Thromb Haemost. 1996 Jul;76(1):9-11 [8819243.001]
  • [Cites] Thromb Haemost. 1994 Jan;71(1):1-6 [8165626.001]
  • (PMID = 16369752.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / antithrombin III-protease complex; 0 / fibrin fragment D; 9000-94-6 / Antithrombin III; EC 3.4.- / Peptide Hydrolases
  •  go-up   go-down


86. Giordano G, Gnetti L, Ricci R, Merisio C, Melpignano M: Metastatic extragenital neoplasms to the uterus: a clinicopathologic study of four cases. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:433-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic extragenital neoplasms to the uterus: a clinicopathologic study of four cases.
  • The aim of this study was to elucidate the clinicopathologic features, the differential diagnostic problems, and the prognostic consequences of patients with metastatic extragenital malignancies to uterus.
  • The patients with metastatic extragenital malignancies to the uterus were evaluated.
  • We considered the metastases in non-genital tract organs at diagnosis of primary neoplasm, the distribution of the metastases in the uterus, and the presence of concomitant metastases in other genital and non-genital tract organs.
  • There were four cases of metastatic extragenital malignancies to the uterus.
  • The other two primary tumors were adenocarcinoma of the cecum and malignant melanoma of the skin.
  • The diagnosis was facilitated by clinical history, revealing the previous primary neoplasm, and by specific immunohistochemical study.
  • Thus, the prognosis of metastatic extragenital malignancies to the uterus alone or simultaneously to the uterus and other organs of the genital tract is poor.
  • Thus, the metastases to the uterus and to other organs of the genital tract can be considered a preterminal event.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Cecal Neoplasms / pathology. Melanoma / secondary. Skin Neoplasms / pathology. Uterine Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515640.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Li X, Qi X, Zhou L, Fu W, Abdul-Karim FW, Maclennan G, Gorodeski GI: P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin. Purinergic Signal; 2009 Sep;5(3):351-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin.
  • The aim of the present study was to better understand the biological significance of P2X(7) receptor expression in normal and cancer human epithelial tissues.
  • P2X(7) receptor and messenger RNA (mRNA) levels were determined in human tissues containing epithelial dysplastic, pre- or early cancerous, and cancer cells, and the levels were compared to those in the corresponding normal epithelial cells within the same tissue of the same case.
  • P2X(7) receptor levels in cancer cells were similar (colon adenocarcinoma) or greater (thyroid papillary carcinoma) than those in the corresponding normal cells.
  • In contrast, in cancer cells of the ectocervix (squamous), endocervix and endometrium (adenocarcinoma), urinary bladder (transitional cell carcinoma), and breast (ductal and lobular adenocarcinomas), P2X(7) receptor levels were lower by about twofold than those in the corresponding normal epithelial cells.
  • Similarly, P2X(7) mRNA levels were lower in uterine, bladder, and breast cancer epithelial tissues by about fourfold than those in the corresponding normal tissues.
  • In addition, P2X(7) receptor levels were decreased already in dysplastic ectocervical cells and pre- or early cancerous endometrial and bladder cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1996 May 3;272(5262):735-8 [8614837.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):1-10 [14997049.001]
  • [Cites] Am J Physiol. 1993 Sep;265(3 Pt 1):C577-606 [8214015.001]
  • [Cites] J Biol Chem. 2008 Oct 17;283(42):28274-86 [18682393.001]
  • [Cites] Endocrinology. 2008 Jan;149(1):389-96 [17947359.001]
  • [Cites] Mol Pharmacol. 2007 Dec;72(6):1447-56 [17785580.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):233-43 [17482244.001]
  • [Cites] FEBS Lett. 2007 Feb 6;581(3):483-8 [17240370.001]
  • [Cites] Curr Pharm Des. 2006;12(34):4411-25 [17168751.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1045-9 [17065062.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):344-7 [16914325.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7386-9 [16885331.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17228-37 [16624800.001]
  • [Cites] Histopathology. 2004 Mar;44(3):206-15 [14987223.001]
  • [Cites] J Neurosci. 2003 Oct 1;23(26):8903-10 [14523092.001]
  • [Cites] J Invest Dermatol. 2003 Aug;121(2):315-27 [12880424.001]
  • [Cites] Aging Cell. 2003 Feb;2(1):39-45 [12882333.001]
  • [Cites] Melanoma Res. 2003 Apr;13(2):137-45 [12690296.001]
  • [Cites] Cell Physiol Biochem. 2003;13(2):93-102 [12649594.001]
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):159-62 [12633871.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4590-6 [12464620.001]
  • [Cites] Physiol Rev. 2002 Oct;82(4):1013-67 [12270951.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23262-7 [11313357.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26792-8 [10854431.001]
  • [Cites] J Urol. 2000 Jun;163(6):2002-7 [10799247.001]
  • [Cites] Oral Oncol. 1999 Nov;35(6):541-7 [10705087.001]
  • [Cites] J Clin Immunol. 1999 Nov;19(6):350-64 [10634209.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):1-2 [16434576.001]
  • [Cites] J Invest Dermatol. 2005 Sep;125(3):482-90 [16117789.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 24;332(1):17-27 [15896293.001]
  • [Cites] Endocrinology. 2005 Jan;146(1):164-74 [15459114.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5568-79 [15319352.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1635-43 [9412459.001]
  • [Cites] Br J Pharmacol. 1999 Aug;127(8):1915-21 [10482924.001]
  • [Cites] Cell Tissue Res. 1999 Jun;296(3):599-605 [10370147.001]
  • [Cites] Cell Biochem Biophys. 1998;29(3):281-306 [9868583.001]
  • [Cites] Receptors Channels. 1998;5(6):347-54 [9826911.001]
  • [Cites] Neurochem Int. 1998 Sep;33(3):209-15 [9759915.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Cell Biol Toxicol. 1998 Mar;14(2):111-20 [9553722.001]
  • [Cites] J Immunol. 1997 Aug 1;159(3):1451-8 [9233643.001]
  • [Cites] Physiol Rev. 1997 Apr;77(2):397-424 [9114819.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:663-98 [1809356.001]
  • [Cites] Arch Toxicol. 1991;65(6):437-44 [1929863.001]
  • [Cites] Int Rev Cytol. 1980;68:251-306 [7014501.001]
  • [Cites] J Invest Dermatol. 1972 Sep;59(3):251-9 [5055188.001]
  • [Cites] Am J Physiol. 1995 May;268(5 Pt 1):C1215-26 [7762615.001]
  • (PMID = 19399640.001).
  • [ISSN] 1573-9538
  • [Journal-full-title] Purinergic signalling
  • [ISO-abbreviation] Purinergic Signal.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG015955
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2717318
  •  go-up   go-down


88. Levakov SA, Zaĭrat'iants OV, Sidorova IS, Opalenov KV, Ali AG: [Detection rates of various serotypes of human papilloma virus in atypical glandular hyperplasia and adenocarcinoma of the endometrium and their immunomorphological features in virus-positive cases]. Arkh Patol; 2007 Mar-Apr;69(2):6-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection rates of various serotypes of human papilloma virus in atypical glandular hyperplasia and adenocarcinoma of the endometrium and their immunomorphological features in virus-positive cases].
  • They were detectable in 35.3 -52.9% of cases of atypical glandular hyperplasia, highly and moderately differentiated adenocarcinoma of the endometrium and only in 17.6% of cases of poorly differentiated adenocarcinomas.
  • The endometrium and tumors showed an increased significant proliferative activity (Ki-67 expression) and reduced expression of receptors to progesterone and, to a lesser degree, to estrogen in 47-83% of virus-positive cases.
  • [MeSH-major] Adenocarcinoma. Endometrial Hyperplasia. Endometrial Neoplasms. Papillomaviridae / isolation & purification. Papillomavirus Infections

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642182.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


89. Jaidane M, Slama A, Bibi M: A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Nov;20(11):1393-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review.
  • We report the first case of an adenocarcinoma arising in an ectopic ureter in a woman and mimicking uterine cervical adenocarcinoma.
  • A 34-year-old woman, previously diagnosed as having bicornuate uterus, presented with post-coital bleeding.
  • After nodule biopsy, the initial diagnosis was adenocarcinoma of the uterine cervix.
  • Pelvic ultrasound and magnetic resonance imaging demonstrated an ectopic tumoral ureter draining a dysplastic pelvic kidney and inserted in the cervix of a bicornuate uterus.
  • Pathological exam demonstrated an adenocarcinoma arising in the ectopic ureter.
  • We suggest that this case could be an argument for recommending regular follow-up for women with ectopic ureter for detecting malignant transformation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Ureter. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging


90. Lowery WJ, Difurio MJ, Sundborg MJ, Leath CA 3rd: Cervical signet-ring cell carcinoma presenting as a synchronous primary carcinoma with uterine adenocarcinoma. Mil Med; 2009 Feb;174(2):212-3
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical signet-ring cell carcinoma presenting as a synchronous primary carcinoma with uterine adenocarcinoma.
  • BACKGROUND: Synchronous primary gynecologic tumors are relatively uncommon with the diagnosis often made following initial surgery.
  • CASE: A multiparous female in her 50s with postmenopausal bleeding was referred to our institution with a biopsy-proven diagnosis of endometrial cancer.
  • Preoperative physical exam revealed a suspicious cervical lesion and upon biopsy she was found to have a signet-ring cell carcinoma of the cervix.
  • Secondary to morbid obesity, the patient was not a candidate for a radical hysterectomy and was treated with curative radiation for stage IB 1 cervical carcinoma and clinical stage I endometrial carcinoma.
  • CONCLUSION: Cervical signet-ring cell carcinoma is an extremely rare pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / pathology. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


91. Shimizudani N, Senba S, Komiyama M, Hatao H, Ito M, Kioi K, Sudo A, Kishi K, Yagyu H, Oh-ishi S, Nakamura H, Matsuoka T: [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2005 Apr;43(4):236-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma].
  • No malignant cells were found in bilateral pleural effusions.
  • Computed tomography (CT) of the abdomen showed a huge mass of the right ovary with a small amount of ascites, suggesting a diagnosis of Meigs syndrome.
  • The ovarian mass and the neighboring organs, including the uterus and the greater omentum, were surgically removed, and then both the bilateral pleural effusion and ascites disappeared after the surgery.
  • The histopathological examination revealed that the mass was clear cell adenocarcinoma of the ovary (stage IIc), indicating that the disease was pseudo-Meigs Syndrome.
  • This is the second report of pseudo-Meigs Syndrome caused by clear cell adenocarcinoma of the ovary in Japan.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Adenocarcinoma, Clear Cell / surgery. Meigs Syndrome / etiology. Ovarian Neoplasms / complications. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Hauth E, Libera H, Kimmig R, Forsting M: [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy]. Rofo; 2006 Mar;178(3):316-23
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
  • [Transliterated title] Magnetresonanztomographie (MRT) des Beckens zur Beurteilung des Endometriums unter Tamoxifentherapie.
  • PURPOSE: The purpose of the study was to determine the value of MR imaging of the pelvis in the diagnostic work-up of the endometrium in breast cancer patients in tamoxifen therapy.
  • The volume of the uterus and cervix and the maximal thickness of the endometrium, junctional zone and myometrium of the uterus were determined and compared to the confidence interval of the parameters in healthy women.
  • The Mann-Whitney U-test was used to identify differences in the volume of the uterus and cervix and in the thickness of the uterine wall layers in both groups.
  • RESULTS: A comparison of the volume of the uterus and cervix and the thickness of the uterine wall layers in the two groups yielded no significant differences.
  • The volume of the uterus and cervix showed no statistical differences between the two groups.
  • The maximal height of the endometrium in the patient group showed a mean of 0.6 cm (range: 0.1 - 2.2 cm), and a mean of 0.4 cm (range: 0.1 - 1.2 cm) in the group of healthy women.
  • In all healthy women the endometrium showed homogeneous signal intensity in the sagittal T2-weighted images.
  • In 12 of the 24 breast cancer patients, the endometrium showed inhomogeneous signal intensity.
  • In 9 of 12 patients with an inhomogeneous endometrium with a thickness equal to or greater than 0.6 cm, histopathology confirmed polyps.
  • In 3 patients endometrium hyperplasia was found.
  • In one patient histopathology revealed a polyp and an endometrium carcinoma in stage T1 a N0.
  • The endometrium carcinoma was not able to be seen via MR imaging.
  • CONCLUSION: MR imaging might be helpful in the diagnosis of endometrium pathologies during tamoxifen therapy.
  • Therefore, MR imaging of the pelvis could be used as a diagnostic tool in the follow-up diagnosis of the endometrium in breast cancer patients in tamoxifen therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Cervix Uteri / drug effects. Endometrial Neoplasms / diagnosis. Endometrium / drug effects. Endometrium / pathology. Magnetic Resonance Imaging / methods. Polyps / diagnosis. Tamoxifen / adverse effects. Tamoxifen / therapeutic use. Uterus / drug effects
  • [MeSH-minor] Aged. Confidence Intervals. Data Interpretation, Statistical. Endometrial Hyperplasia / chemically induced. Endometrial Hyperplasia / diagnosis. Endometrial Hyperplasia / pathology. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiology Information Systems. Time Factors


93. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Underexpression of maspin has been reported in breast and prostatic cancers, but in some cancers such as ovarian, colorectal and pancreatic carcinoma, it was found to be up-regulated.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Immunohistochemical staining was also performed on 10 cases of endometrial cancer (6 FIGO stage I cases and 4 FIGO stage III cases) as well as 15 normal endometrium.
  • Semi-quantitative RT-PCR revealed that the expression of maspin was significantly up-regulated in both stage I (p<0.01) and stage III (p<0.01) endometrial cancer compared with normal endometrium.
  • However, no significant difference in maspin expression was demonstrated between stage I and stage III endometrial cancer.
  • Immunostaining of all tissue sections revealed an immunopositive signal in the nuclei of the normal or cancerous endometrial glandular cells.
  • In 60% of the cancer cases, cytoplasmic staining was also evident.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • Cytoplasmic immuno-expression of maspin is common in endometrial cancer.
  • It may play a role in the malignant transformation of human endometrial tissue.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Gene Expression Regulation, Neoplastic. Serpins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


94. Chura JC, Brooker D, Downs LS Jr: Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature. Gynecol Oncol; 2006 Oct;103(1):336-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
  • BACKGROUND: Carcinoma of the urinary bladder that occurs after urinary diversion is a rare entity.
  • We report a case of an adenocarcinoma arising in a defunctionalized bladder that presented as locally advanced endometrial carcinoma.
  • The patient underwent anterior pelvic exenteration for a locally advanced mucinous carcinoma thought to be arising from the uterus and invading into the bladder.
  • Final pathology, however, was consistent with a primary bladder carcinoma.
  • CONCLUSION: Carcinoma developing in the bladder after urinary diversion presents at an advanced stage and has associated poor overall survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Urinary Diversion / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793125.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Fiore G, Nencini C, Cavallo F, Capasso A, Bader A, Giorgi G, Micheli L: In vitro antiproliferative effect of six Salvia species on human tumor cell lines. Phytother Res; 2006 Aug;20(8):701-3
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracts were screened for their possible antitumoral activity by MTT test on nine human cancer cell lines: glioblastoma (DBTRG-05MG, T98G, U-87MG), colorectal adenocarcinoma (WiDr and HT-29), prostate adenocarcinoma (MDA Pca2b), choriocarcinoma (JEG-3), endometrium adenocarcinoma (HEC-1A) and B lymphoblast (CIR).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676297.001).
  • [ISSN] 0951-418X
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


96. Hoskins PJ, Le N: Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1200-1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus.
  • CA125 is a well-recognized marker for endometrial cancer.
  • Uterine malignant mixed müllerian tumors (MMMTs) are increasingly being recognized as an aggressive adenocarcinoma, not a sarcoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinosarcoma / blood. Carcinosarcoma / diagnosis. Mixed Tumor, Mullerian / blood. Mixed Tumor, Mullerian / diagnosis. Uterine Neoplasms / blood. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217961.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


97. Keightley MC, Sales KJ, Jabbour HN: PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. BMC Cancer; 2010 Sep 14;10:488
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.
  • BACKGROUND: An increase in cancer cell invasion and microvascular density is associated with a poorer prognosis for patients with endometrial cancer.
  • In endometrial adenocarcinoma F-prostanoid (FP) receptor expression is elevated, along with its ligand prostaglandin (PG)F2α, where it regulates expression and secretion of a host of growth factors and chemokines involved in tumorigenesis.
  • This study investigates the expression, regulation and role of a disintegrin and metalloproteinase with thrombospondin repeat 1 (ADAMTS1) in endometrial adenocarcinoma cells by PGF2α via the FP receptor.
  • METHODS: Human endometrium and adenocarcinoma tissues were obtained in accordance with Lothian Research Ethics Committee guidance with informed patient consent.
  • Signal transduction pathways regulating ADAMTS1 expression in Ishikawa cells stably expressing the FP receptor to levels seen in endometrial cancer (FPS cells) were determined by quantitative RT-PCR analysis.
  • RESULTS: ADAMTS1 mRNA and protein expression is elevated in endometrial adenocarcinoma tissues compared with normal proliferative phase endometrium and is localised to the glandular and vascular cells.
  • CONCLUSIONS: These data demonstrate elevated ADAMTS1 expression in endometrial adenocarcinoma.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] BMC Cell Biol. 2010;11:8 [20092633.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1255-62 [11583953.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3437-43 [11705860.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):501-8 [12054629.001]
  • [Cites] Mol Hum Reprod. 2002 Dec;8(12):1065-70 [12468638.001]
  • [Cites] Eur J Pharmacol. 2003 Mar 28;465(1-2):39-41 [12650831.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1825-32 [12679480.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:183-90 [12814950.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23656-65 [12716911.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Trends Pharmacol Sci. 2003 Jul;24(7):335-40 [12871665.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):649-63 [15023336.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Obstet Gynecol. 1995 Oct;86(4 Pt 1):479-85 [7545803.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):556-62 [8995297.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Annu Rev Immunol. 1997;15:707-47 [9143705.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13912-7 [9593739.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23844-52 [15843381.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2452-67 [16314835.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12210-7 [16505480.001]
  • [Cites] Hum Reprod. 2006 Aug;21(8):1990-9 [16675485.001]
  • [Cites] EMBO J. 2006 Nov 15;25(22):5270-83 [17082774.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):36-44 [16905765.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3683-90 [17440080.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Jun;7(4):343-53 [17979629.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):56-61 [18059462.001]
  • [Cites] Curr Protoc Cell Biol. 2001 May;Chapter 12:Unit 12.2 [18228316.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9 [18061438.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(4):700-9 [17996481.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2466-77 [17968320.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Apr;41(4):800-10 [18775505.001]
  • [Cites] Nat Genet. 2009 May;41(5):619-24 [19396168.001]
  • [Cites] J Biol Chem. 2009 Jun 12;284(24):16325-33 [19349275.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Genes Dev. 2009 Aug 15;23(16):1882-94 [19608765.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1793(12):1917-28 [19819266.001]
  • [Cites] J Biol Chem. 2010 Jan 22;285(4):2463-73 [19915008.001]
  • [Cites] FEBS Lett. 2000 Aug 4;478(3):241-5 [10930576.001]
  • (PMID = 20840749.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calmodulin; 0 / Culture Media, Conditioned; 0 / NFATC Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; B7IN85G1HY / Dinoprost; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAMTS1 protein, human
  • [Other-IDs] NLM/ PMC2944181
  •  go-up   go-down


98. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM: Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol; 2010 Jan;116(1):10-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
  • OBJECTIVE: To study patterns of recurrence and survival outcomes in patients with surgical stage I, grade 3 endometrioid adenocarcinoma of the endometrium (EA) treated with various treatment modalities.
  • Sixty-one patients (35%) had lymphovascular space invasion (LVSI) and a mean of 18.9 lymph nodes (LNs) was removed.
  • CONCLUSIONS: Patients with stage IB/IC, grade 3 endometrioid adenocarcinoma have a significant risk for extra-pelvic recurrence.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2010 Jun;117(3):507; author reply 507-8 [20189231.001]
  • (PMID = 19875158.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


99. Manchana T, Khemapech N: Endometrial adenocarcinoma in young Thai women. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma in young Thai women.
  • OBJECTIVE: To evaluate the clinicopathological characteristics and survival analysis in endometrial adenocarcinoma women younger than the age of 40 years compare to older women.
  • METHODS: Medical records of 423 endometrial adenocarcinoma patients who received primary surgical treatment at King Chulalongkorn Memorial Hospital during 1996-2005 were reviewed.
  • RESULTS: Up to 10% (42/423) of endometrial adenocarcinoma patients were younger than the age of 40 years.
  • Moreover, synchronous ovarian cancer seemed to be higher in young patients (7.1% and 2.9%, p > .05).
  • CONCLUSIONS: Obesity was the only independent factor associated with endometrial adenocarcinoma in young patients.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712975.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


100. Yoshida M, Watanabe G, Shirota M, Maekawa A, Taya K: Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev; 2005 Dec;51(6):707-14
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
  • Ovarian dysfunction leading to hormonal imbalance plays a crucial role in uterine carcinogenesis in rats as well as women.
  • However, the effects of a reduction in primordial follicles at birth on uterine adenocarcinoma development have hitherto not been determined.
  • The present study was therefore conducted using female Donryu rats, a high incidence rat strain of uterine adenocarcinoma.
  • The incidence of uterine adenocarcinomas and multiplicity of uterine neoplastic lesions were significantly increased by the 5.0 mg/kg, but not the 2.5 mg/kg busulfan treatment.
  • These results provide evidence that the reduction of primordial follicles promotes uterine adenocarcinoma development in rats in association with an earlier occurrence of the persistent estrus status.
  • [MeSH-major] Adenocarcinoma / etiology. Antineoplastic Agents, Alkylating / pharmacology. Busulfan / pharmacology. Endometrial Neoplasms / etiology. Ovarian Diseases / chemically induced. Ovarian Follicle / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177545.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Gonadal Steroid Hormones; G1LN9045DK / Busulfan
  •  go-up   go-down






Advertisement